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ABSTRACT OF THE DISSERTATION
The Bidirectional Relationship between the Circadian Clock and Alzheimer’s disease
by
Patrick Sheehan
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2022
Professor Josh Rubin, Chair

The circadian clock and inflammation have a well-described bidirectional relationship in the
peripheral immune system: the circadian clock regulates inflammatory responses, but
inflammation also impacts oscillatory gene transcription controlled by the clock. The purpose of
this thesis work is to understand if manipulation of the circadian clock can impact Alzheimer’s
disease pathology, and if pathology itself can alter the circadian clock and its outputs. Here, I
show that astrocyte-specific disruption of the circadian clock via deletion of the clock gene
Bmal1 surprisingly decreased intra-neuronal protein pathologies. Further investigation found
that deletion of the circadian clock resulted in a transcriptomic profile in astrocytes that allowed
for easier degradation of misfolded proteins. Interestingly, by looking at single nuclei
sequencing from patients with Alzheimer’s disease, we found similar transcriptional profiles in
astrocytes of people with Alzheimer’s disease. By knocking out the circadian clock in
astrocytes, we inadvertently showed that targeting protein degradation pathways in astrocytes
could reduce protein pathologies. To show that pathology could impact the circadian clock, we
used ribosomal profiling to isolate RNA from astrocytes or microglia in vivo every two hours

ix

over a 24 hour period from wild-type mice, or mice with amyloid plaque pathology, and found
that amyloid plaque pathology had a very large impact on genes that were being rhythmically
expressed, a phenomenon called circadian reprogramming. We also observed circadian
reprogramming in astrocyte and microglia during normal aging. Interestingly, we found that
about half of the 48 Alzheimer’s disease risk factor genes were rhythmically expressed in at least
one of our datasets, suggesting that circadian clock may in fact play a prominent role in the
progression of disease pathology. Together, these findings do in fact show that circadian
rhythms and Alzheimer’s disease pathology have a bidirectional relationship and that targeting
the circadian system for future therapeutics could be beneficial for alleviating disease.
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Chapter 1: Introduction
1.1 Circadian Rhythms and Neurodegeneration
1.1.1 Circadian Rhythms – a brief introduction
The majority of life on the planet displays some circadian rhythmicity. Even prokaryotes
such as cyanobacteria have circadian rhythms(Bhadra, Thakkar, Das, & Pal Bhadra, 2017).
Plants display numerous circadian rhythms including upregulating photosynthesis as the sun
comes out(Hennessey & Field, 1991). It is thought that circadian rhythms have thus evolved to
anticipate and coordinate activities based on time of day(Buhr & Takahashi, 2013). Humans
have well-known circadian rhythms in many processes including their sleep-wake cycles, blood
pressure, cholesterol production, melatonin secretion, body temperature(Albrecht & Eichele,
2003). How these circadian rhythms are generated at the molecular level has been studied for
many years and the discovery of which was awarded the Nobel Prize in 2017. While we have
known for quite some time that these circadian rhythms exist in each of these systems, we are
just now learning how these rhythms, and the maintenance of those rhythms, could be important
in treating disease. Furthermore, what happens to our physiology when we disrupt our circadian
rhythms through things like social jetlag or flying to a different time zone? Studies have shown
consistently that heart attacks increase the first few days after we switch our clock for daylight
savings time, suggesting that maintaining a consistent circadian rhythm is important for
preserving health(Manfredini et al., 2019).

1

1.1.2 The Molecular Clock
Just like the ubiquitous nature of circadian rhythms in life, circadian clocks are also
ubiquitous at the cellular level. Nearly every nucleated cell has its own circadian clock that
controls cell-specific circadian rhythms. These rhythms at the cellular level eventually give rise
to systemic circadian rhythms like our sleep-wake cycle. The molecular circadian clock inside
of every cell is an endogenous oscillator that is entrained by extrenal cure, particularly (but not
exclusively) light cycles. This molecular clock ticks by using a transcriptional translational
feedback loop. While there are many proteins that feed into this molecular clock that can
influence its rhythmicity, we can simplify the molecular clock into a few critical proteins. In the
positive arm of the clock, which drives transcription of clock genes, BMAL1 and CLOCK
proteins heterodimerize and bind to Ebox motifs in the genome. BMAL1 and CLOCK drive
transcription of hundreds of different proteins, including their own repressors; PER1, PER2,
PER3, CRY1, and CRY2, all of which make up the negative limb of the clock as they function to
repress activity of BMAL1 and CLOCK. This transcription-translation feedback loop occurs on
about a 24 hour cycle, entrained by light, meaning that BMAL1 peaks in expression in every cell
in the body at about the same time of day, every day(Takahashi, 2017). Cells are able to
synchronize their rhythmic activity throughout the body through a small area in the brain called
the suprachiasmatic nucleus(Yamaguchi et al., 2003). While this circadian feedback loop
impacts the rhythmic expression of circadian transcription factors, it also drives rhythmic
transcription of hundreds of other genes that give rise to rhythmicity in cell function.
Interestingly, 5-20% of genes transcribed by a single cell have been found to be rhythmically
expressed, likely through the oscillations in circadian clock proteins(Takahashi, 2017). This
rhythmic transcription of proteins outside of the core circadian clock translates to cell-specific
2

rhythms in function. For example, many leukocytes show circadian rhythms in their trafficking
to different tissues in the body, and hepatocytes in the liver predict eating habits to rhythmically
express genes involved in fat metabolism(Eckel-Mahan et al., 2013a; Nathan, Gibbs, Rainger, &
Chimen, 2021). Circadian rhythms, driven by the molecular circadian clock produces important
aspects of physiology that can very often be overlooked. However, recent data has showns that
the breakdown of these circadian clocks can be detrimental and possibly lead to disease.

Fig 1.1. The core molecular clock. BMAL1 and CLOCK operate in the nucleus where they
bind to Ebox motifs in order to drive transcription of their own repressors (PER’s and CRY’s).
The negative limb of the clock then comes back into the nucleus to repress BMAL1 and CLOCK
activity. Figure from: (Masri & Sassone-Corsi, 2018)
3

1.1.3 Circadian Rhythms in Neurodegeneration
Circadian rhythm dysfunction in the form of disruption in sleep wake cycles is a
symptom of most neurodegenerative diseases. Many patients with Alzheimer’s disease (AD),
Parkinson’s disease and Huntington’s disease, present with some form of sleep-wake
disturbance, generally manifesting in excessive daytime sleepiness and increased time spent
awake at night(Nassan & Videnovic, 2022). One important question that is yet unanswered in
the field is whether circadian rhythm dysfunction can contribute to the progression of disease
pathology, or if neurodegeneration alternatively impacts circadian rhythms. Interestingly,
disruption in sleep-wake cycles in patients with AD have been observed prior to the onset of
other clinical symptoms, suggesting that dysfunctional circadian rhythms may not be a direct
result of disease pathology(Leng, Musiek, Hu, Cappuccio, & Yaffe, 2019). Other studies have
also reported increased risk of dementia and cognitive decline in people experiencing circadian
disruption, such as those people doing shift work(Schlosser Covell et al., 2012; Tranah et al.,
2011). Interestingly, in a mouse model of amyloid plaques deposition, when the circadian clock
is knocked out via deletion of BMAL1, there was a resulting increase in the amount of plaque
pathology in the hippocampus(Kress et al., 2018). This evidence suggests that circadian rhythms
may in fact play a role in the progression of disease pathology. Thus, understanding circadian
rhythms and its effects in disease may be a therapeutic target in the future for treating these
neurodegenerative diseases. However, a current issue in the field revolves around how quantify
circadian disruptions in different mouse models. Standardizing these quantification can lead to a
better understanding of if/how circadian rhythms contribute to disease pathogenesis.
4

1.2 Circadian Dysfunction in Mouse Models of Alzheimer’s
Disease
Sheehan P.W. and Musiek E. S. 2020. Frontiers in Neuroscience

Circadian dysfunction has been described in patients with symptomatic Alzheimer’s
disease (AD), as well as in presymptomatic phases of the disease. Modeling this circadian
dysfunction in mouse models would provide an optimal platform for understanding mechanisms
and developing therapies. While numerous studies have examined behavioral circadian function,
and in some cases clock gene oscillation, in mouse models of AD, the results are variable and
inconsistent across models, ages, and conditions. Ultimately, circadian changes observed in
APP/PS1 models are inconsistent across studies and do not always replicate circadian
phenotypes observed in human AD. Other models, including the 3xTG mouse, tau transgenic
lines, and the accelerated aging SAMP8 line, show circadian phenotypes more consistent with
human AD, although the literature is either inconsistent or minimal. We summarize these data
and provide some recommendations to improve and standardize future studies of circadian
function in AD mouse models.

1.2.1 Introduction
Numerous human studies have demonstrated that changes in circadian function are
common in Alzheimer’s disease (AD) patients and contribute to disease morbidity. Circadian
changes observed in AD patients include circadian fragmentation and decreased amplitude of
circadian rhythms, which generally manifest as increased wakefulness at night and increased
5

napping during the day (Ancoli-Israel et al., 1997; Satlin, Volicer, Stopa, & Harper, 1995). These
changes are observed in patients with preclinical AD pathology, meaning that they harbor
amyloid plaque and/or tau pathology but do not yet have cognitive symptoms (Musiek et al.,
2018). They are also evident in the mild cognitive impairment stage and worsen with disease
severity. In symptomatic AD patients, a phase delay has been described, which means that the
peak of activity occurs later in the day (Ancoli-Israel et al., 1997; Satlin et al., 1995). This phase
delay has been hypothesized as a possible cause of “sundowning” in AD, or increased confusion
and agitation in the afternoon and evening(Volicer, Harper, Manning, Goldstein, & Satlin, 2001).
As the disease progresses, some patients develop severe fragmentation of circadian rhythms,
leading to poor behavioral differentiation between day and night (Ancoli-Israel et al., 1997;
Hatfield, Herbert, Van Someren, Hodges, & Hastings, 2004). The underlying mechanisms
governing this circadian dysfunction are not well understood, creating a need for accurate mouse
models which replicate some of these phenotypes. Circadian biology can be a daunting field for
AD researchers. Thus, a brief introduction to common circadian parameters may be helpful
(Banks and Nolan, 2011). Circadian period is the length of time of a full circadian cycle. This
can only be measured under “constant conditions” (usually meaning constant darkness for mice,
indicated as “DD”). Most mice have a period just under 24 h in constant darkness; shortening or
lengthening of period can be indicative of changes in the circadian clock itself. Amplitude
indicates the difference between the peak and nadir of activity, averaged over several days. In
general, mice should have minimal activity during the light phase (as they are nocturnal and
sleeping), but are very active during the dark phase. Increased activity during the light phase and
decreased activity in the dark would indicate blunted circadian amplitude, as is seen in AD
patients. However, generally hyperactive animals can be overactive during the dark phase and
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have a high amplitude, while hypoactive animals may be inactive during both phases and show
artificially blunted amplitude. If these differences in baseline activity levels are altered in
transgenic mouse models, it may lead to difficulty interpreting circadian behavioral analyses.
Phase indicates the time of day of peak activity, averaged over several days. A later peak (phase
delay) is seen in AD patients. Fragmentation indicates a breakdown of circadian timing to drive
consolidated periods of rest and activity. Fragmentation usually leads to a blunted amplitude, or
can be measured by a non-parametric test called intradaily variability (IV) (Huang et al., 2002).
Of note, circadian rhythms in behavior are largely driven by the activity of the suprachiasmatic
nucleus (SCN) of the hypothalamus, the “master clock” of the body. Degeneration or
dysfunction of the SCN, as has been described in human AD (Swaab, Fliers, & Partiman, 1985)
can lead to weaker circadian synchronization, increased fragmentation, and decreased amplitude
(Nakamura et al., 2011). At a molecular level, circadian rhythms are driven by oscillations of
circadian clock genes in the SCN and other tissues. These circadian clock genes include Bmal1
and Clock, which function as transcription factors to drive transcription of their own repressors:
Per1, Per2, Per3, Cry1, Cry2, and Rev-erbα and β. Levels of these clock gene transcripts oscillate
with a 24- h period in most tissue and are entrained to daily light cycles (Buhr & Takahashi,
2013). Thus, measurement of clock gene oscillations in SCN and other tissues can be a
molecular marker of clock function. Over the past 20 years, a considerable literature has arisen in
which circadian parameters have been examined in various AD models. Many of these studies
have described modest changes in AD model mice, though these changes vary considerably
between studies. The sheer number of distinct AD mouse models, as well as the age- and sexdependency of pathology in these models, has complicated things further. Thus, it remains
difficult to identify AD models which consistently and faithfully recapitulate the findings
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observed in human AD. Below, we have attempted to divide AD mouse models into their most
common categories, and to review the existing literature on circadian rhythms in these models.
These data are compiled in Table 1. While not an exhaustive or systematic review, the included
studies represent many of the vast majority of published studies, as well as the most commonly
cited and most thorough studies of circadian function in AD mouse models (other species were
excluded), and thus provide what we believe is a representative sample of the literature.

1.2.2 APP and APP/PS1 Mice
There are a multitude of different transgenic mouse lines which express human amyloid
precursor protein (APP) and in some cases human presenilin 1 (PS1), both harboring a variety of
AD-associated mutations which promote amyloid-beta (Aβ) generation and aggregation. These
mice accumulate amyloid plaque pathology at variable ages and in varying brain regions
depending on the specific transgene and sex of the animal. APP/PS1 mice also vary in the
biochemical character of the plaques that are formed, as well as the presence or absence of
intracellular amyloid. Presumably, APP and APP/PS1 mice model the earliest stage of AD, that
being amyloid plaque deposition, as most of these models develop minimal tau pathology or
overt neurodegeneration. Humans with preclinical AD or MCI have been shown to have
decreased circadian amplitude, increased fragmentation, and, in MCI, a phase delay (Naismith et
al., 2014; Ortiz-Tudela et al., 2014). However, results of circadian studies in APP and APP/PS1
mice do not clearly demonstrate consistent AD-like phenotypes. Several studies have shown
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Table 1: Summary of studies of circadian function in mouse models of AD.

increased activity in these mouse lines during the dark phase (the active phase of mice), as well
as increases in circadian amplitude (Ambrée et al., 2006; Bedrosian, Herring, Weil, & Nelson,
2011; Otalora et al., 2012; Oyegbami et al., 2017). Aside from this, the wide variety of subtle
and oft-conflicting circadian phenotypes in APP and APP/PS1 mouse studies can be appreciated
in Table 1. Thus, a clear circadian phenotype which models early human AD has not emerged
from the literature. Recently, Kent et al. conducted a very thorough study of APPswe/PS1dE9
mice, a commonly used APP/PS1 model which developed plaques around 6 months old (mo).
This study, which examined mice at multiple ages and included a variety of light manipulations
and Per2-luciferase rhythm recordings in SCN and various peripheral tissues (such as liver, lung,
and spleen), revealed only a minimal delay in activity onset after lights-off in transgenic mice
(Kent et al., 2019). Moreover, several studies demonstrate circadian changes which precede
amyloid plaque pathology, suggesting possible strain or transgene effects, though an effect of
soluble Aβ cannot be excluded (Bedrosian et al., 2011; Ni et al., 2019; Ortiz-Tudela et al., 2014;
Oyegbami et al., 2017). While not a true circadian study, Roh et al. (2012) demonstrated blunting
of amplitude in diurnal rhythms in sleep and brain lactate levels in APPswe/PS1dE9 mice, which
was reversible with immunization of an anti-Aβ antibody, suggesting that amyloid pathology
may indeed contribute to some aspects of rhythm dysfunction. Paul et al. (2018) examined the
TgSwDI APP mutant mouse and observed shortened period and increased variability in activity
onset/offset that were associated with blunted amplitude of neuronal firing in the SCN, providing
an electrophysiological basis for rhythm disturbance. A human BACE1 knockin mouse, which
drives intracellular amyloid accumulation without APP overexpression, showed decreased dark10

phase activity but no other major circadian alterations, though assessment was limited (Plucińska
et al., 2014). An issue with the wide array of APP and APP/PS1 is that these transgenes are
driven by specific promoters (including the Thy1 and prion protein promoters) which may not
express in all relevant cell types and regions (such as the SCN and circadian output pathways).
This variability of transgene expression may account for some of the inconsistency in circadian
phenotypes across APP/PS1 models. While APP and APP/PS1 models have been the most
studied in terms of circadian function, the wide array of unique APP and APP/PS1 lines, as well
as the possible amyloid-independent effects of these transgenes on activity level, has led to a
murky literature which undermines the utility of these models for examining circadian changes.

1.2.3 Tauopathy and 3xTG Mice
Tau transgenic mice overexpress the human MAPT gene with disease-causing mutations
(often P301S or P301L) and are often used to model tauopathy associated with AD. Unlike APP
mice, tau transgenics generally develop striking neurodegeneration and premature death. The
Tg4510 mouse, an aggressive model of tauopathy which expresses MAPTP301L (Ramsden et
al., 2005), develops a lengthened circadian period and decreased circadian amplitude, as well as
seemingly blunted circadian clock gene expression in the hypothalamus and hippocampus when
measured at two times of day (Stevanovic et al., 2017). These changes were observed at 8 mo,
when severe tau pathology is present. SCN tau pathology was also noted in this study. A study of
MAPTP301S PS19 mice, which focused exclusively on sleep, showed a decrease in sleep and an
increase in wakefulness, suggesting a possible underlying circadian deficit, very late in the
disease progression (Holth, Mahan, Robinson, Rocha, & Holtzman, 2017). While promising,
further studies of circadian function in tauopathy models are needed to determine how robust and
consistent these changes are across tau models and studies.
11

The 3xTG mouse was introduced in 2003 as a murine model of both of the hallmark
neuropathologies of human AD: amyloid plaques and tau tangles. 3xTG mice express three
transgenes (APP Swedish, MAPT P301L, and PS1 M146V) and develop amyloid plaque
pathology starting around 4 months, with aggregated tau pathology beginning around 12 months
(Oddo et al., 2003). Several studies have examined circadian function in 3xTG mice, some of
which describe phenotypes which more closely resemble human AD. However, results are
fraught with inconsistency across different studies. Wu et al. (2018) show a striking decrease in
amplitude, less daily activity, and fragmentation (increased IV) in 6 mo 3xTG mice, reminiscent
of human AD circadian dysfunction. Knight et al. (2013) report no changes in activity profile in
6 mo 3xTG mice and go on to show an increased amplitude in daily activity and temperature
rhythm by 10 months. Moreover, Sterniczuk et al. (2010) show increased amplitude and daytime
activity in four month old male mice while female mice show a decreased amplitude by 11
months. Finally, Adler et al. (2019) showed a shortened period and decreased amplitude in 3xTG
mice which was ameliorated by inhibiting casein kinase 1δ and 1ε, enzymes that are important
for the degradation of PER proteins and maintenance of core clock function. Thus, while the
3xTG mouse shows some promise as a more accurate model of AD-like circadian changes, the
inconsistency across studies makes interpretation difficult. It is also notable that these circadian
changes were all observed at ages prior to the accumulation of considerable tau pathology. Of
note, a different triple-transgenic mouse expressing APP, hTau, and PS1, specifically in the
forebrain (PLB1 mice), did not show obvious circadian deficits, suggesting that SCN-dependent
expression of pathology may be important (Platt et al., 2011).
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1.2.4 Other AD Models
The Senescence Accelerated Mouse, line P8 (SAMP8 mouse) is a unique, non-transgenic
mouse line that has been selectively bred to promote accelerated aging (Butterfield & Poon,
2005; Holth et al., 2017; Ramsden et al., 2005; Stevanovic et al., 2017). SAMP8 mice are usually
compared to another SAM mouse line which is aging-resistant (SAMR1) as a control. SAMP8
mice spontaneously develop mild amyloid-beta accumulation, mild tauopathy, synapse loss, and
cognitive impairment early in life, and have been used as a model of AD (E. Morley, A. Farr, B.
Kumar, & J. Armbrecht, 2012). SAMP8 mice show striking circadian changes, including
increased activity during light phase, decreased circadian amplitude, and fragmentation
(McAuley, Miller, Beck, Nagy, & Pang, 2002; Miyamoto et al., 1986; Pang, Miller, & McAuley,
2004), although this has not always been reported (Sánchez-Barceló, Megias, Verduga, &
Crespo, 1997). Like APP mice, they show a general hyperactivity phenotype, which complicates
interpretation. However, the striking circadian changes observed in several studies suggest that
SAMP8 mice have potential as a model of age and AD related circadian dysfunction.
Apolipoprotein E (ApoE) genotype is the major genetic risk factor for sporadic AD, with the E4
allele imparting increased risk. Apoe−/− mice have been reported to have more variable activity
rhythms in DD, impaired entrainment, and alterations of SCN clock gene expression rhythms
(Zhou et al., 2016). However, APP mice expressing human ApoE4 do not have more severe
circadian changes than APP with wild type mouse ApoE (Boggs, Kakalec, Smith, Howell, &
Flinn, 2017; Graybeal et al., 2015). This is an unexpected finding, as ApoE4 increases amyloid
pathology in mice (Castellano et al., 2011) and might be expected to exacerbate circadian
dysfunction. More detailed studies which incorporate pathology assessments are needed.
Injection of Aβ peptide into the brain of wild type mice has also been used to model AD, and has
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been reported to lengthen period and blunt clock gene rhythms in the SCN (Navigatore-Fonzo et
al., 2017), and to alter expression patterns of Apoe and other mRNAs in the hippocampus (Wang
et al., 2016), though this model is not widely used.

1.2.5 Impact of AD pathology on Clock Gene Expression
Differences in circadian outputs at the level of sleep-wake cycles can generally be
correlated to changes in the molecular clock. However, differences in clock gene expression in
studies of AD models are generally difficult to interpret. For example, some studies have
suggested decreased expression of clock genes in AD models before the onset of pathology.
Oyegbami et al. (2017) show a decrease in Cry1 and Cry2 in the medulla pons of 2- month-old
APPswe/PS1dE9 mice, while Ni et al. (2019) show a decrease in Bmal1, Per2, and Rev-erbα in
isolated cortical microglia from 2-month-old APP-KI mice (both well before plaque deposition
occurs). Song et al. (2015) showed blunting of rhythmic BMAL1 protein levels prior to disease
pathology in the SCN of 2 mo 5xFAD mice (an APP/PS1 mutant model). These may indicate an
effect of soluble Aβ, or effects of the transgene/mutation introduced, highlighting the importance
of these assays at multiple ages over the course of disease pathology. Wu et al. (2018) showed a
slight phase delay and decreased expression of Per1/2 in the SCN of 3xTG mice, while Ma et al.
(2016) showed altered rhythms in hippocampal Bace2 and Apoe mRNA. Other studies in AD
models have examined clock gene expression at one or two time points throughout the circadian
cycle, usually early morning and early evening, in some case showing a loss of variation in AD
mice (Bellanti et al., 2017; Duncan et al., 2012; Lee et al., 2020; Stevanovic et al., 2017). While
these can be used to make general conclusions, it is difficult to interpret if clock genes are
changing amplitude, or if there is just a difference in phase of expression of that particular gene.
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Detailed time courses of circadian gene expression in different brain regions of AD mouse
models at pathology-bearing ages are needed to thoroughly address this issue.

1.2.6 Recommendations for Circadian Studies in Mouse Models of
Neurodegeneration
Considering the complexity of this literature, we offer here some recommendations for
future studies of circadian rhythms in AD mouse models: Constant conditions: Mouse activity
must be recorded under constant conditions (usually constant darkness or dim light) in order to
make firm conclusions about the circadian system. Many studies of behavioral rhythms in AD
model mice are conducted in 12:12 h light:dark, which introduces factors related to light
intensity, as well as the issue of “masking,” or behavioral suppression by light which occurs
independently of the circadian system. Furthermore, previous studies have shown some rhythm
abnormalities in AD models in 12:12 h light:dark cycles that resolve in constant conditions
(Stevanovic et al., 2017; Sundaram et al., 2019). Moreover, tissue harvests for clock gene
expression studies should also be conducted in DD, as light can impact clock gene expression
(Moriya, Horikawa, Akiyama, & Shibata, 2000). Correlation with pathology: Many studies of
circadian function in AD models do not describe or quantify the degree of pathology in their
mice. It is important to demonstrate the degree of pathology (amyloid plaque burden, tau
pathology, etc.) in the mice at the same age and in the same sex that are used for behavioral
studies. While previous papers can be used as general guidelines, mice of a similar genotype can
have very different pathology when raised in different colonies and facilities. Moreover,
circadian deficits arising in AD mice well before pathology may suggest behavioral effects of
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transgene overexpression, rather than true pathology-driven changes. Indeed, behavioral changes
in 3xTG can be dependent on genetic background (Pardossi-Piquard et al., 2016). Finally, it is
potentially important to assess the degree of pathology in the SCN in these mouse models, to see
if there is a direct effect on the central pacemaker. SCN pathology has only been analyzed in a
few models, as 3xTG mice do not have plaques or tangles at 12 months, while Tg4510 mice do
have SCN tau pathology at 8 months (Knight et al., 2013; Stevanovic et al., 2017). Even in the
absence of clear plaque pathology, it is possible that soluble Aβ species (such as oligomers) may
impact SCN function, though levels and dynamics of soluble Aβ species in the SCN have not
been examined. Finally, human post-mortem AD SCN generally shows neuronal loss and tau
pathology, rather than plaques, which may not be recapitulated in amyloid-based models (Stopa
et al., 1999). Multiple endpoints: Most studies focus on rhythms in wheel running as the primary
endpoint. While some have included temperature or some limited clock gene investigation, little
is known about other circadian endpoints. Peripheral clocks, for instance, could be disrupted
even in the face of normalappearing wheel running behavior. Some studies do examine Per2luciferase rhythms in SCN explants (Kent et al., 2019), clock gene expression in SCN (Song et
al., 2015; Stevanovic et al., 2017), or SCN firing rate (Giladi et al., 2018). Integration of multiple
endpoints in future studies may reveal important phenotypes. Sex and age considerations: Sex
has a strong effect on both circadian rhythms, as well as on pathology in AD models. In general,
female APP and APP/PS1 mouse lines develop amyloid plaques faster than males, while this
relationship is reversed for the accumulation of tau pathology in MAPT mice (Carroll et al.,
2010; Sun et al., 2020). Furthermore, there is potentially conflicting effects of sex on circadian
biology that could further complicate these studies (Bailey & Silver, 2014). Thus, sex must
always be considered. Age also has strong effects on circadian function, but is less clearly tied to
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amyloid/tau pathology in mouse models, as specific transgene/mutations can drive pathology at
vastly different ages. In some cases, mice develop plaques when they are still young, while in
others age and amyloid pathology come together and may interact (Wisor et al., 2005). Thus, the
effects of age itself, and the rate of pathology accumulation, must be considered.

1.2.7 Conclusion
In summary, while many AD mouse models exhibit alterations in circadian behavioral
rhythms and/or gene expression, these changes are generally not consistent across studies or
models, or have questionable relevance to human AD. As such, it is still unclear if specific
protein pathologies (such as amyloid or tau aggregation) directly drive circadian changes, or if
these observed changes are due to other factors (such as transgene overexpression, genetic
background, sex, or age). As new AD models are developed, circadian studies must consider
basic study design principles, degree of pathology, age, and sex, in order to provide interpretable
and consistent results.

17

Chapter 2: Astrocytic BMAL1 Regulates
Protein Aggregation in Mouse Models of
Alpha-Synuclein and Tau pathology
2.1 Abstract
The core circadian clock transcription factor BMAL1 modulates glial activation and
influences amyloid-beta deposition in mice. However, the effects of BMAL1 on intracellular
protein aggregation and spreading are unknown. Here we observed that global post-natal deletion
of Bmal1 suppressed toxic protein aggregation and consequent microgliosis in mouse models of
tauopathy and alpha-synucleinopathy. Bmal1 deletion induced cell-autonomous astrocyte
activation, and astrocyte-specific Bmal1 deletion was sufficient to elicit protection in both
models. Bmal1 deletion induced astrocyte expression of BAG3, a chaperone critical for
macroautophagy, and enhanced lysosomal uptake of alpha-synuclein by astrocytes in a BAG3dependent manner. BAG3 was highly expressed while BMAL1 was decreased in activated
astrocytes clusters in human single nucleus RNAseq datasets from both Alzheimer and Parkinson
Diseases patients. Our findings show that early astrocyte activation induced by Bmal1 deletion
protects against tau and alpha-synuclein aggregation and suggest that astrocyte BMAL1-BAG3
may be a therapeutic target for neurodegenerative diseases.

2.2 Introduction
Astrocyte activation is a ubiquitous feature of neurodegenerative diseases and is induced
in the setting of pathogenic protein aggregation(Escartin et al., 2021; Sofroniew, 2015). Recent
studies demonstrate that astrocyte activation is highly transcriptionally diverse and dependent on
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disease context(Burda et al., 2022; Habib et al., 2020; Hasel, Rose, Sadick, Kim, & Liddelow,
2021). Some modes of astrocyte activation can promote phagocytosis and degradation of protein
aggregates to limit neurodegenerative pathology(Ceyzériat et al., 2018). In other settings,
activated astrocytes can be polarized toward neurotoxic phenotypes and promote protein
aggregation and neurodegeneration(Ceyzériat et al., 2018; Liddelow & Barres, 2017). Thus, the
identification of factors which can promote protective modes of astrocyte activation has
considerable therapeutic importance.
Previous work form our group has identified the core circadian transcription factor
BMAL1 (aka ARNTL) as a potent regulator of astrocyte activation (Lananna et al., 2018;
Musiek et al., 2013). BMAL1 mediates circadian transcriptional regulation via
heterodimerization with CLOCK or NPAS2 to regulate gene expression in a tissue-specific
manner. Global deletion of Bmal1 not only renders mice behaviorally and transcriptionally
arrhythmic(Radcliffe et al., 2000), but also alters the expression of many non-rhythmic genes,
driving distinct transcriptional changes in different brain cell types (McKee, Lananna, & Musiek,
2020). Among the most striking phenotypes observed following Bmal1 deletion is astrocyte
activation, which is cell-autonomous and associated with a unique transcriptional profile
(Lananna et al., 2018; McKee et al., 2022; Musiek et al., 2013). Functionally, global post-natal
deletion of Bmal1 in the APP/PS1-21 mouse model of AD exacerbates extracellular β-amyloid
plaque formation, while astrocyte-specific Bmal1 deletion had no impact on plaque accumulation
in this model (Kress et al., 2018). However, the cell type-specific effects of Bmal1 disruption on
other aspects of neurodegeneration remain unexplored.
While β-amyloid accumulates in plaques in the extracellular space(Cirrito et al., 2005),
other disease-associated proteins, including tau and alpha-synuclein (α-Syn), aggregate within
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neurons and exhibit spreading to neighboring cells, including trans-synaptic propagation to other
neurons (Frost, Jacks, & Diamond, 2009). Tau aggregation is a hallmark of AD and numerous
other neurodegenerative diseases termed “tauopathies”. α-Syn pathology defines PD and related
“synucleinopathies,” including Dementia with Lewy Bodies and Multiple Systems Atrophy and
is also present in nearly half of AD cases (Toledo et al., 2014). Patients with AD or PD exhibit
disrupted circadian rhythms and altered clock gene expression(Musiek & Holtzman, 2016;
Videnovic et al., 2014), and mouse tauopathy and alpha-synucleinopathy models show disruption
of circadian function as pathology advances(Kudo, Loh, Truong, Wu, & Colwell, 2011;
Stevanovic et al., 2017). Notably, a recent study identified BMAL1 as one of the top upstream
transcription factors driving astrocyte transcriptional responses to tauopathy in mice (Jiwaji et
al., 2022). However, it is unknown if disruption of the circadian clock directly influences tau or
alpha-synuclein pathology.
Here, we explored the effects of global post-natal Bmal1 deletion on tau and alphasynuclein aggregation in mouse models. Unexpectedly, we found that global Bmal1 deletion was
protective against intra-neuronal protein aggregation and consequent microglial activation. We
observed that astrocyte-specific deletion of Bmal1 replicates this protective phenotype in both
models. This effect is attributable to early cell-autonomous astrocyte activation induced by
Bmal1 deletion and astrocytic expression of the macroautophagy chaperone Bag3. Finally, we
find that BAG3 and BMAL1 show reciprocal expression patterns in activated astrocytes from
human AD brain. Our findings demonstrate that early astrocyte activation can mitigate tau and
synuclein pathology in vivo and show that the circadian clock protein BMAL1 mediates a
protective astrocyte activation state.
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2.3 Results
2.3.1 Global Bmal1 deletion prevents tau aggregation in P301S Mice
We employed a tamoxifen-inducible global Bmal1 KO mouse which we have previously
shown develops behavioral and transcriptional circadian arrhythmicity and diffuse astrogliosis
after post-natal tamoxifen treatment, but which avoids developmental confounds related to
germline Bmal1 deletion (Kress et al., 2018; Yang et al., 2016). We crossed this mouse to the
widely used P301S PS19 model of tauopathy (Yoshiyama et al., 2007) to generate four mouse
genotypes: CAG-CreERT2 -; Bmal1f/f; P301S- (termed CTRL), CAG-CreERT2 +;Bmal1f/f;P301S(termed gKO for global Bmal1 KO), CAG-CreERT2 -; Bmal1f/f;P301S+ (termed P301S), and
CAG-CreERT2 +; Bmal1f/f;P301S+ (term gKO;P301S). We administered tamoxifen to delete
Bmal1 at two months of age (well before onset of tau pathology), then harvested mice for
pathology at eight months of age at which time mice typically exhibit moderate tau pathology
(Fig 2.1C). We used all male P301S mice because they developed pathology earlier and more
consistently than females. As observed previously, loss of Bmal1 triggered significant
astrogliosis which we assessed using GFAP immunohistochemistry in CA1 of the hippocampus
(Fig 2.1A). We also confirmed suppression of several known Bmal1 transcriptional targets in
gKO and gKO;P301S mice (Fig 2.1B). Male P301S mice generally develop brain atrophy by
9mo (Shi et al., 2017), so we analyzed mice in this experiment at 8mo when atrophy is typically
minimal, anticipating that Bmal1 deletion would exacerbate neurodegeneration and brain
atrophy. We analyzed hippocampal atrophy by measuring the thickness of the CA1 and
hippocampal granule layers and saw no difference between any genotypes, suggesting that these
mice were sacrificed prior to overt neurodegeneration and that Bmal1 deletion does not
exacerbate hippocampal neurodegeneration in this model (Fig 2.1D).
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Figure 2.1. Global Bmal1 deletion induces astrogliosis but no degeneration in P301S mice.
(A) Representative images of CTRL and gKO mice with GFAP (red) and BMAL1 (green). (B)
qPCR analysis of downstream Bmal1-target genes, Nr1d1 and Dbp in cortex tissue CTRL, gKO,
P301S, and gKO;P301S mice harvested at 8mo. (C) Schematic of the experimental paradigm
used. (D) Hippocampal CA1 thickness and Granule layer thickness quantified with DAPI
staining.

Next, we examined the burden of tau pathology. Assessment of phosphorylated tau (pser202, p-thr205) pathology with AT8 immunohistochemistry showed a large increase in P301S
mice compared to CTRL, but no significant difference between P301S and gKO;P301S mice in
either hippocampus or piriform cortex, two regions that readily accumulate tau pathology in this
model (Fig 2.2A) (Yoshiyama et al., 2007). To determine differences in soluble and insoluble
tau species in these mice, we examined total tau levels by ELISA in cortical tissue lysates
subjected to sequential extraction in detergents of increasing strength. Similar to the AT8
immunostaining, the more soluble RAB and RIPA fractions of tau were not significantly
different between P301S and gKO;P301S mice. However, there was significantly less insoluble
tau (70% formic acid fraction) in gKO;P301S mice as compared to P301S, suggesting that highly
insoluble tau species were decreased by deletion of Bmal1 (Fig 2.3A). Surprisingly,
quantification of misfolded, paired helical filament tau using the antibody MC1 also showed a
decrease in gKO;P301S mice (Fig 2.3B). We also observed a decrease in highly aggregated
Thioflavin S+ aggregates in the gKO;P301S brain as compared to P301S mice (Fig 2.3C). In
order to query potential differences in morphological subtypes of tau pathology affected by loss
of Bmal1, we classified AT8 immunohistochemistry as fitting into one of four patterns of
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increasing severity in the hippocampus (Shi et al., 2017). Again, gKO;P301S mice had
substantially less of the most severe type 4 staining than P301S mice, suggesting that global
Bmal1 deletion may mitigate pathological tau pathology in vivo (Fig 2.3D). These data
demonstrate that global deletion of Bmal1 results in decreased aggregated tau pathology without
altering total tau or soluble phospho-tau levels.

A.

Figure 2.2. Global deletion of Bmal1 does not alter hyperphosphorylated tau levels. (A)
Representative images and quantification of AT8 staining in hippocampus of CTRL, gKO,
P301S, and gKO;P301S mice. N = 8-11 mice per group.
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Figure 2.3. Global Bmal1 deletion mitigates tau pathology. (A) Quantification of fractionated
tau between RAB (soluble tau), RIPA (slightly insoluble tau) and 70% formic acid
(insoluble/aggregated tau) cortical fractions. N = 6-9 mice per group. (B) Representative images
of MC1 immunoreactivity with quantification in the piriform cortex of P301S (left) and
gKO;P301S mice (right). N = 6-7 mice per group. (C) Thioflavin-S staining/quantification in
P301S and gKO;P301S mice. N = 9-11 mice per group. (D) Hippocampal AT8 staining divided
into severity patterns, with type 4 being most severe.

2.3.2 Global Bmal1 deletion mitigates microglia activation in P301S Mice
Aggregated tau pathology is associated with pronounced microglia and astrocyte
activation in P301S mice (Shi et al., 2017). Thus, we examined a customized panel of transcripts
associated with neuroinflammation and glial activation by microfluidic qPCR in cortex tissue
from CTRL, gKO, P301S, and gKO;P301S mice. P301S mice exhibited marked upregulation of
all neuroinflammatory markers tested, including disease-associated microglial (DAM) markers
(Keren-Shaul et al., 2017) Spp1, Trem2, Tyrobp, Clec7a, and Apoe. Conversely, expression of all
neuroinflammatory markers was attenuated in gKO;P301S compared to P301S mice (Fig
2.4A). We constructed a PCA plot of inflammatory gene expression and observed minimal
overlap between P301S mice and each of the other three genotypes (Fig 2.4B,C), suggesting that
gKO;P301S mice are more similar to CTRL mice.
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Figure 2.4. Global Bmal1 deletion in P301S mice results in reduced inflammation at the
transcriptomic level. (A) Transcriptional analysis of inflammatory genes related to microglial
activation (including DAM genes) between all four mouse genotypes. N = 6-11 mice per
genotype. (B) Two different PCA analyses show separation of P301S mice form all other
genotypes.
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To corroborate the decrease in microglia activation in gKO;P301S mice, we quantified
microglial branching morphology using high-resolution confocal images from Iba1
immunohistochemistry from hippocampus. Microglia in P301S mice had fewer branches per cell
than gKO;P301S mice, indicating an activated microglia phenotype (Fig 2.5B). We also
analyzed CD68 staining in the hippocampus as a marker of microglial phagocytic activation
(Schafer et al., 2012), and saw that gKO;P301S had fewer Iba1+/CD68+ microglia, suggesting
again that Bmal1 deletion attenuated or prevented microglia activation (Fig 2.6A). Finally we
assessed astrocyte activation by immunostaining for GFAP and found that unlike microgliosis,
P301S and gKO;P301S mice had similar, high levels of astrogliosis in the
hippocampus. Interestingly, GFAP expression was increased in gKO mice to a similar degree as
P301S or gKO;P301S mice, suggesting that Bmal1 deletion alone is sufficient to induce chronic
astrogliosis which reaches a ceiling effect and is not further exacerbated by tau pathology (Fig
2.6B). This reduction in microglial inflammation parallels reductions in insoluble tau
aggregation in gKO;P301S mice, suggesting that Bmal1 deletion prevents downstream
inflammation by preventing tau aggregation and subsequent injury. However, astrogliosis occurs
early as a result of Bmal1 deletion, suggesting that this early astrocyte activation may play a role
in mitigating tau aggregation and subsequent microglial activation in gKO;P301S mice.
Together, these data show that global Bmal1 deletion reduces tauopathy-associated microgliosis
while independently driving early astrogliosis.
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B.

Figure 2.5. Global Bmal1 deletion in P301S prevents microglia activation. (A) 20x confocal
images and quantification of CD68 immunoreactivity in the hippocampus and piriform cortex of
P301S (top) and gKO;P301S mice (bottom). N = 9-11 mice per group. (B) Representative
skeletonized microglia and quantification of branching. N = 5-6 mice per genotype with 6-9
microglia quantified per mouse.
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Figure 2.6. Global Bmal1 deletion induces chronic astrogliosis. (A) Representative images of
hippocampal GFAP immunoreactivity and quantification. (B) qPCR analysis of astrogliosisrelated genes across genotypes. N=5-12 mice per group.
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2.3.3 Global deletion of Bmal1 suppresses alpha synuclein pathology and
microgliosis
Because global Bmal1 deletion results in increased accumulation of extracellular amyloid
plaques (Kress et al., 2018) but we observed a decrease in intra-neuronal tau aggregates, we
tested the effect of Bmal1 deletion on another model of intra-neuronal protein pathology. Here,
we used a fibril injection model of alpha-synuclein pathology in which alpha-synuclein
preformed fibrils (αSyn PFFs) are injected into the striatum and cause seeding and spreading of
endogenous mouse synuclein (Luk et al., 2012; Volpicelli-Daley, Luk, & Lee, 2014; Volpicellidaley et al., 2011). As before, we used global inducible Bmal1 knockout mice (CAG-CreERT2 +;
Bmal1f/f; again termed gKO) and Cre-;Bmal1f/f littermate controls (CTRL). Tamoxifen was
administered at two months of age to gKO and CTRL mice, followed by unilateral intrastriatal
injection of αSyn PFFs one month later (Fig 2.7A). To test whether gKO mice develop
astrogliosis prior to PFF injection, gKO and CTRL mice were analyzed for GFAP one month
post-tamoxifen. As expected, GFAP was significantly increased, suggesting that astrogliosis is
present in gKO at the time of PFF injection as a result of Bmal1 deletion (Fig 2.7B).
We examined the burden of aggregated, phosphorylated (Ser129) ⍺-synuclein (pSyn) in
these mice three months after PFF injection and observed a reduction in pSyn pathology in the
cortex of PFF-injected gKO mice as compared to PFF-injected CTRL mice (Fig 2.9A). There
was also a significant reduction in microglial branching in the striatum of PFF-injected CTRL
mice, indicating a more activated phenotype as compared to gKO mice (Fig 2.9B). To
understand the relationship between the pathology and glial activation, we performed a linear
regression between immunohistochemical pSyn burden and both IBA1 and GFAP staining. We
observed a positive correlation between IBA1 and pSyn staining but no correlation between
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B.

Figure 2.7. Bmal1 deletion induces acute astrogliosis prior to onset of α-synuclein
pathology. (A) Schematic of the experimental paradigm showing intra-strial injection of α-Syn
PFFs one month post-tamoxifen administration. (B) Images and quantification of acute
astrogliosis one month after tamoxifen administration in CTRL (top) and gKO (bottom)
mice. N=4 mice per group.

32

A.

B.

Figure 2.8. Global Bmal1 deletion suppresses α-synuclein pathology. (A) Images and
quantification of phosphorylated synuclein (pSyn) pathology in CTRL and gKO mice at 6mo., N
= 8 mice per group. (B) Representative images and quantification of pSyn (red) and GFAP
(cyan) immunoreactivity, in mice from C. N = 5 mice per group.
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Figure 2.9. Global Bmal1 deletion reduces microglia activation in a PFF model of αsynuclein pathology. (E) IBA1 (green) and CD68 (red) staining, colocalization and
quantification in mice from C. N = 6 mice per group. (F) Microglia branching analysis and
quantification in the cortex from mice with synuclein pathology. N = 6 mice per group, n = 4-7
microglia per mouse.

GFAP and pSyn, suggesting that microgliosis is linked to αSyn pathology but astrogliosis is not,
presumably due to astrogliosis driven by Bmal1 deletion (Fig 2.9C,D). These data show that
global loss of Bmal1 results in reduced synuclein pathology and attenuated microglia activation,
which is similar to what we observed in the tauopathy model. Taken together, these results show
that global Bmal1 deletion induces early astrocyte activation and suppresses αSyn spreading
pathology and subsequent microglial activation.

2.3.4 Astrocyte-specific deletion of Bmal1 prevents both synuclein and tau
pathologies
Previous work from our lab (Lananna et al., 2018), as well as our data here, shows that
astrogliosis induced by loss of Bmal1 is cell-autonomous, such that astrocyte-specific Bmal1
deletion produces a similar degree of astrogliosis as global Bmal1 deletion (Fig 2.10A). We
hypothesized that this cell-autonomous effect of Bmal1 deletion on astrocyte activation might
underlie the protective effects observed with global Bmal1 deletion in tau and synuclein models.
In order to test this hypothesis, we used inducible, astrocyte-specific Bmal1 KO mice (Aldh1l1CreERT2 +; Bmalf/f; termed aKO), which we were previously generated and characterized in our
lab (Lananna et al., 2018; McKee et al., 2022). To assess if astrocyte-specific Bmal1 knockout
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A.

Figure
2.10. Astrocyte-specific Bmal1 deletion induces cell-autonomous astrogliosis.
(A) Representative images of GFAP (red) and BMAL1 (green) from WT and aKO mice, 4
months after tamoxifen.

could reduce tau pathology, we crossed aKO mice to the P301S PS19 line used previously,
generating P301S (Cre-;Bmal1f/f;P301S+) and aKO;P301S mice (Aldh1l1CreERT2+;Bmal1f/f;P301S+). Cre-;Bmalf/f littermate control mice were again termed CTRL. We
treated mice with tamoxifen at two months of age and harvested at 9mo to analyze pathology
(Fig. 2.11A). As observed in global Bmal1 knockout mice, immunostaining for
hyperphosphorylated tau with AT8 showed no difference in pathology between P301S and
aKO;P301S mice (Fig. 2.11B). However, MC1 immunostaining for aggregated tau
demonstrated a significant decrease in the amount of tau pathology in the hippocampus and
piriform cortex of aKO;P301S mice, suggesting that loss of Bmal1 specifically in astrocytes is
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Figure 2.11. Astrocyte-specific Bmal1 deletion is sufficient to reduce tau pathology.
(A) Experimental paradigm used in the tauopathy model with P301S and aKO;P301S mice. (B)
Representative images and quantification of AT8 (B) and MC1 (C) in P301S and aKO;P301S
mouse hippocampus and piriform cortex. N = 11-12 mice per group.

sufficient to reduce tau pathology (Fig. 2.11C). To determine whether astrocytic Bmal1 deletion
was sufficient to also mitigate alpha-synuclein pathology, CTRL and aKO mice were subjected
to a-syn PFF injection using the same methods and timing as previously described (Fig
2.12A). Astrocytic Bmal1 deletion recapitulated the phenotype observed in the global BMAL1
gKO mice, with aKO mice showing reduced synuclein pathology across multiple brain regions
with even a further increase in astrogliosis (Fig. 2.12B).
In order to evaluate a possible microglia-specific effect of Bmal1 deletion on α-synuclein
spreading, we generated inducible, microglia-specific, Bmal1 knockout mice (Cx3cr1CreERT2+;Bmal1f/f). We confirmed suppressed Bmal1 expression in microglia isolated from the
brain of these mice, and observed no obvious spontaneous microglial activation in vivo after
tamoxifen treatment (Fig 2.13B,C). We treated a cohort of microglial Bmal1 KO mice (and Crelittermate controls) with tamoxifen and injected α-syn PFFs as before. We observed no effect of
microglial Bmal1 deletion on aggregated alpha-synuclein pathology in this model, suggesting
that reduction in alpha-synuclein pathology is not dependent on microglial Bmal1 (Fig 2.13A).
We next investigated whether the timing of astrocyte activation is critical to this
phenotype by injecting intra-striatal α-Syn PFFs one month before tamoxifen administration,
such that astrogliosis occurred after initiation of synuclein seeding (Fig 2.14A). When the order
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Figure 2.12. Astrocyte-specific Bmal1 deletion is sufficient to reduce α-synuclein pathology.
(A) Schematic of the α-Syn PFF model using aKO mice. (B) Representative images and
quantification of pSyn pathology (red) and astrogliosis (green) in WT and aKO mice in the
frontal cortex and piriform cortex at 6mo. N= 7-9 mice per group.

39

A.

B.

C.

40

Figure 2.13. Microglia-specific Bmal1 deletion does not impact α-synuclein pathology. (A)
Representative images of GFAP (green) and pSyn (red) with quantification of pSyn in the frontal
cortex and piriform cortex. Mice were treated with TAM at 2mo, injected with α-syn PFFs at
3mo, and harvested at 6mo. N=5-7 mice/group. (B) qPCR validation of genes downstream of
BMAL1 from isolated microglia using Cx3cr1 Cre- or Cx3cr1 Cre+ mice. (C) qPCR analysis of
inflammatory markers from the cortex of Cx3cr1 Cre- and Cx3cr1 Cre+ mice. N = 6-8 mice per
group.

of tamoxifen and PFF injection was reversed in this manner, there was no statistically-significant
reduction in pSyn pathology (though a trend toward reduction in pSyn pathology in one brain
region was seen), suggesting that early activation of astrocytes is important for reducing
pathology (Fig 2.14B). In all, these results show that deletion of Bmal1, specifically in
astrocytes, is sufficient to reduce both tau and alpha-synuclein pathologies.

2.3.5 Bmal1-dependent astrocytic Bag3 expression modulates alpha-synuclein
uptake
Previous work from our lab showed that deletion of Bmal1 in astrocytes causes an altered
transcriptional profile (McKee et al., 2022) that presumably leads to astrocyte activation and we
postulate this contributes to the reduction of tau and synuclein pathologies reported here. To
explore this in more detail, we analyzed an existing whole transcriptome dataset derived from
bulk cerebral cortex tissue from aKO and Cre- controls (McKee et al., 2022), in order to identify
differentially expressed genes (DEGs) involved in mitigation of tau/synuclein pathology. We
performed GO analysis of significant DEGs (using a permissive uncorrected p < 0.05 cutoff for
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Figure 2.14. Loss of Bmal1 after α-synuclein PFF injection has less impact on
pathology. (A) Experimental timeline inverting the times of TAM administration and PFF
injection in Bmal1 aKO mice (and Cre- controls). (B) Representative images of GFAP (red) and
pSyn (green). Quantification of both GFAP and Psyn in the frontal cortex, piriform cortex and
striatum. N=7-8 mice/group.
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Figure 2.15. Astrocytes up-regulate protein catabolism genes in responsive to Bmal1
deletion. (A) GO analysis of genes differentially expressed in cortex of aKO mice (vs. Crecontrols) with p-value less than 0.05 and fold change greater than 1.5. Top ten GO pathways
shown. (B) Genes most significantly dysregulated in the “Regulation of Protein Catabolic
Process” GO pathway with a difference of greater than 1.5 fold and adjusted p value of less than
0.1 between genotypes. N = 5 mice sequenced per group. (C) Representative images and
quantification of BAG3 (red) and GFAP (yellow) in WT and aKO mice, n = 3-4 mice. (D) Bag3
mRNA levels (n=2) in primary astrocytes treated with siRNAs.
exploratory analysis) to better understand pathways dysregulated in aKO mice. Regulation of
Protein Catabolic Process emerged as one of the most upregulated pathway (Fig 2.15A), and 71
genes included in this pathway were also differentially expressed in aKO cortex. To further
refine genes of interest in this pathway, we excluded genes the expression of which changed less
than 1.5 fold and/or had an adjusted p value of greater than 0.1. After applying these filters, four
genes remained, two were upregulated in aKO mice, and two were downregulated (Fig
2.15B). Of these four genes, we focused our attention on Bag3, as it is a critical driver of
macroautophagy (Cao et al., 2017; Fu et al., 2019; Ji et al., 2019; Lin et al., 2022) and recently
identified as a PD-associated gene by la recent genome wide association study (Nalls et al.,
2019). We confirmed that Bag3 mRNA was consistently upregulated in Bmal1 KO brain tissue
across several existing transcriptomic datasets, but was not increased in neuron-specific Bmal1
KO mice (Fig 2.16A) (Griffin et al., 2019; Lananna et al., 2018). We examined Bag3 expression
in samples from CTRL, gKO, P301S, and gKO;P301S, and observed that Bag3 was strongly
upregulated in gKO mice and in P301S mice with no further increase in gKO;P301S mice, just
like other astrocyte activation transcripts (Fig 2.15C) To better understand BAG3 expression in
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Figure 2.16. Global Bmal1 deletion results in upregulation of BAG3. (A) Bag3 mRNA
expression in published transcriptomics datasets from Nestin-Cre;Bmal1(f/f) (cortex, 9mo,
Musiek et al.), germ-line Bmal1 KO (hippocampus, 5mo, Griffin et al.), Camk2a-iCre;Bmal1 KO
(cortex, 4mo, McKee et al.). Note no increase in Camk2a-Cre neuron-specific Bmal1 KO mice.
(B) 20x confocal images of BAG3 and GFAP immunoreactivity in gKO mice, with
quantification. Quantification of the volume of GFAP, BAG3 and GFAP/BAG3 colocalization
from 3D reconstructions of confocal z-stacks.
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aKO mice, we performed double-label immunohistochemistry for BAG3 and GFAP and found
that BAG3 protein is indeed highly expressed in activated astrocytes in aKO mice. Using
confocal microscopy coupled with 3D surface rendering, we found that the most of BAG3
volume colocalized with GFAP (Fig 2.15D). We also observed increased astrocytic BAG3
expression in the global Bmal1 knockout (gKO) mice (Fig 2.16B).
To investigate mechanisms by which Bmal1 deletion in astrocytes might mitigate tau
and/or α-synuclein pathology, we examined astrocyte phagocytosis of α-Syn aggregates in vitro.
We prepared α-Syn PFFs conjugated to the pH-sensitive dye pHrodo Red, fluorescence of which
is generally indicative of uptake into phagosomes or lysosomes. In primary mouse astrocytes
cultures, siRNA targeting Bmal1 caused a consistent ~80% suppression of mRNA of
downstream Bmal1 target, Dbp (Fig 2.17B), and resulted in a significant increase in Bag3
expression compared to the siRNA-scramble control. Bag3 siRNA strongly suppressed Bag3
mRNA levels in primary astrocyte cultures, while treatment with both Bmal1 and Bag3 siRNA
together resulted in a strong knockdown of both genes (Fig 2.17A). Two days after siRNA
knockdown, we added pHrodo-PFFs to the culture of astrocytes for three hours to allow pHrodoPFF uptake, then washed the cells and incubated for an additional 24 hours (Fig
2.17C). Knockdown of Bmal1 significantly increased astrocyte pHrodo-PFF signal, indicating
increased phagocytosis and lysosomal uptake. Bag3 knockdown alone had no effect on α-Syn
uptake, while knockdown of Bmal1 and Bag3 together significantly attenuated the Bmal1dependent increase in PFF lysosomal uptake (Fig 2.17D). This finding suggests that loss of
BMAL1 increases astrocytic α-Syn PFF uptake and degradation in a manner that is at least
partially dependent on BAG3. To understand if BAG3 upregulation is sufficient to increase
pHrodo-PFF uptake, we created an AAV2/8 vector which drives BAG3 expression under the
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Figure 2.17. Astrocytic BAG3 modulates α-synuclein uptake downstream of Bmal1. (A)
Bag3 and (B) Dbp mRNA levels (n=4) in primary astrocytes treated with siRNAs. (C)
Experimental paradigm for phrodo-PFF uptake assay. (D) pHrodo-PFF uptake by primary mouse
astrocytes after knockdown of Bmal1, Bag3, or both, N = 5 independent experiments and n = 2
technical replicates per experiment. (E) Bag3 upregulation in primary astrocytes using a serial
dilution of a Bag3-overexpression AAV. (F) pHrodo-PFF uptake after AAV-mediated Bag3
overexpression in primary astrocytes, N = 4 independent experiments and n = 2 technical
replicates per experiment.

Gfap promoter. This vector increased Bag3 expression in a dose-dependent manner in primary
astrocyte cultures, as compared to a similar AAV8-Gfap-eGFP control vector (Fig 2.17E). Using
this viral vector in the same pHrodo-PFF uptake system, we found that astrocytes overexpressing
Bag3 display increased uptake of pHrodo-PFFs (Fig 2.17F). Our data suggests that BAG3 is not
necessary for basal α-Syn uptake by astrocytes, but that astrocytic Bag3 overexpression is
sufficient to drive increased α-Syn lysosomal uptake. Furthermore, Bmal1 knockdown enhances
astrocyte α-syn PFF lysosomal uptake at least in part via a Bag3-dependent mechanism.

2.3.6 Reciprocal regulation of BMAL1 and BAG3 in activated astrocytes in
human Alzheimer’s Disease and Parkinson’s Disease brain

Our data suggest that astrocytic BMAL1 expression could be manipulated to induce a
neuroprotective astrocyte activation state which includes enhanced expression of BAG3. BAG3
expression in neurons can induce autophagic degradation of tau or synuclein, but less is known
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Figure 2.18. BAG3 is upregulated in bulk AD datasets and is a PD GWAS hit. (A) BAG3
expression in bulk RNAseq samples from human control and Alzheimer’s disease patients. Data
from Zhang et al. (B) BAG3 expression in control, asymptomatic AD patents, and symptomatic
AD patients from Mount Sinai Brain Bank. (C) A) PD GWAS browser
(https://pdgenetics.shinyapps.io/GWASBrowser/) shows SNPs associated with PD in
BAG3 intronic regions.
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Figure 2.19. Reciprocal regulation of BMAL1 and BAG3 in activated astrocytes in human
AD brain. (A) Single nuclei sequencing of samples from 70 control, sAD and ADAD patients
clustered into general cell types. (B) t-SNE of 38,677 total astrocytes subclustered into 5 distinct
clusters. (C) Featureplots of homeostatic and activated astrocyte markers to define astrocyte
clusters of interest. (D) Subclustering of just the homeostatic and activated astrocyte clusters
with (E) a heatmap of their corresponding markers. (F) Violin plots showing the distribution of
expression scores for BAG3 and ARNTL genes in homeostatic and activated astrocytes.

about astrocytic BAG3, with only a single paper describing BAG3 staining in human AD and PD
brain (Seidel et al., 2012). Thus, we sought to characterize BMAL1/ARNTL and BAG3 gene
expression in astrocytes in human neurodegenerative disease. We used a public microarray
database (Zhang et al., 2013) and found that BAG3 was significantly upregulated in the brain of
AD patients compared to controls (adj.p = 2.2x10-16) (Fig 2.18A). Notably, BAG3 was not
increased in asymptomatic AD, suggesting that BAG3 expression may occur later in disease
course (Fig 2.18B). To specifically investigate the expression of BAG3 in astrocytes in AD, we
mined a single nucleus sequencing dataset that includes autosomal dominant AD (ADAD),
sporadic AD, and neuropathology-free controls (Brase et al., 2021) for ARNTL and BAG3
expression (Fig 2.19A). First, we identified the astrocyte cluster in this dataset and were able to
divide this group into five distinct subclusters (Fig 2.19B). We identified a homeostatic GFAPlow (Astro.0) subcluster which expressed homeostatic transcripts (LUZP2, SLC7A10, MFGE8),
as well as an activated GFAP-high (Astro.1) subcluster which expressed (AQP4, ID3, MYOC,
GFAP) (Fig 2.19C). Thus, we focused our analysis on Astro.0 and Astro.1, hereafter termed
homeostatic and reactive astrocytes, respectively (Fig 2.19D,E). Interestingly, we found that
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reactive astrocytes downregulate ARNTL (Adj.P= 2.06 x 10-118) and upregulate BAG3
(Adj.P=9.32 x 10-45) (Fig 2.19F). Overall, these analyses support the concept that BAG3 is
specifically expressed in reactive astrocytes in the human brain, often in a reciprocal manner
with ARNTL/BMAL1. Moreover, we analyzed existing PD GWAS data and observed that SNPs
in regulatory regions of BAG3 are also associated with risk of developing PD (Fig 2.18C). Our
data in humans suggests that not only is SNPs in BAG3 associated with risk of developing PD,
but BAG3 is also significantly expressed in activated astrocytes in human AD in a reciprocal
manner as BMAL1, pointing to BMAL1 as a potential therapeutic target to induce a
neuroprotective phenotype in astrocytes.

2.4 Discussion
Here we show that loss of the circadian clock transcription factor Bmal1 in astrocytes
induces an activation state that is capable of reducing intra-neuronal protein pathologies
including tau and synuclein. We demonstrate that early induction of astrocyte activation via
Bmal1 deletion prior to extensive protein aggregation can limit the formation of insoluble tau and
aSyn aggregates and prevent downstream microglial activation. Finally, we show that these
effects of Bmal1 deletion are partially dependent on increased astrocytic expression of BAG3,
and provide evidence for BAG3 upregulation in a cluster of DAA-like astrocytes in human
autosomal-dominant AD, suggesting this may represent a neuroprotective astrocyte cluster. Our
data reveal BMAL1 as a mediator of an astrocyte activation program which includes BAG3
expression and which prevents the spread of intra-neuronal protein pathologies.
A persisting question in the field of neurodegeneration is whether astrocyte activation,
which observed almost ubiquitously, is protective or deleterious. Efforts to genetically impair
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astrocyte activation have yielded mixed results across different models. Transcriptomic profiling
studies of astrocytes under different pathologic conditions suggest that multiple modes of
astrocyte activation exist, only a few of which, such as A1/A2 (Liddelow & Barres, 2017) and
DAAs (Habib et al., 2020), have been characterized. However, only a few studies have
demonstrated astrocyte-specific manipulations which can prevent intracellular protein
aggregation (such as that seen with tau and synuclein). Constitutive JAK2 activation leads to
STAT3 phosphorylation and astrogliosis, and was found to reduce intracellular huntingtin
aggregation. JAK2-STAT3 activation in astrocytes induced proteasomal activity and expression
of the chaperone DNAJB1, though BAG3 was not increased in this model (Ceyzériat et al.,
2018). Conversely, deletion of the astrocytic α2 Na+/K+-ATPase suppressed astrogliosis and
prevented tauopathy in P301S mice (Mann et al., 2022). Interestingly, astrocytic α2 Na+/K+ATPase increased astrocytic lipocalin-2 (Lcn2), which in turn promoted inflammation and
neurodegeneration in P301S mice. Although Bmal1 deletion induces robust astrocyte activation,
it does not induce expression of Lcn2 (Lananna et al., 2018), which may bias or lea? BMAL1deficient astrocytes toward a protective phenotype. Thus, Bmal1 deletion appears to induce a
distinct activation state, although additional profiling is needed to compare and contrast the
pathways regulated in each. While tau and α-synuclein form intraneuronal aggregates,
proteopathic seeding occurs via transmission from cell to cell (Donnelly & Pearce, 2019). In
drosophila, glia serve as intermediaries in neuron-to-neuron transfer of huntingtin species
(Donnelly & Pearce, 2019). Tau aggregates also spread from neurons to astrocytes in vivo in
mice (Maté De Gérando et al., 2021), providing astrocytes an opportunity to degrade
proteopathic species and suppress pathological spreading. Because we observed increased
phagocytosis of α-Syn PFFs in Bmal1-deficient astrocytes in vitro, we hypothesize that Bmal1-
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deficient astrocytes take up protepathic species released from neurons and degrade them in a
BAG3-dependent manner. Alternatively, astrocytes could indirectly promote degradation of
protein aggregates by neurons, perhaps by providing chaperone proteins to neurons via exosomes
(Haim et al., 2015). Thus, we cannot fully exclude the possibility that Bmal1-deficient astrocytes
signal to neurons and enhance neuronal proteostasis.
A major question stemming from our findings is whether the observed effects of
astrocytic Bmal1 deletion are related to disruption of circadian rhythms. It is well established that
astrocyte BMAL1 can regulate expression of non-rhythmic transcripts (Lananna et al., 2020),
and that BMAL1 (and all circadian clock proteins) exerts some cellular functions that are not
related to circadian rhythmicity (Yu & Weaver, 2011). In this case, the effect of Bmal1 deletion
on astrocyte activation is unlikely to be tied to rhythms, as our aKO mice have preserved
circadian rhythms of behavior. However, it remains possible that loss of the cell-intrinsic
transcriptional rhythms within astrocytes causes chronic cellular adaptations that lead to
astrocyte activation and Bag3 expression. Future studies will be needed to determine how other
clock gene mutations or non-genetic circadian disruptions impact tauopathy and synuclein
pathology. Notably, a recent analysis of differentially-expressed genes in astrocytes from both
APP/PS1 and P301S tau mouse models identified BMAL1 as a major transcriptional regulator of
disease-related astrocyte gene expression, independent of any circadian analysis (Jiwaji et al.,
2022). Regardless of the role of circadian rhythms, our work identifies BMAL1 as a key
regulator of neuroprotective astrocyte activation, and reveal BMAL1 and its downstream
pathways in astrocytes as novel neuroprotective therapeutic targets. Our findings suggest that
astrocytic BAG3 represents one of these downstream targets.
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While it may seem surprising that Bmal1 deletion exerts a protective effect in our tau and
α-synuclein mouse models, several others studies suggest that Bmal1 deletion has mixed effects
across neurological disease models. Our group has shown that global or brain-specific Bmal1
deletion causes spontaneous synaptic loss and oxidative stress in mouse brain (Musiek et al.,
2013), and can accelerate amyloid plaque deposition in APP/PS1 transgenic mice (Kress et al.,
2018). However, in the mouse experimental autoimmune encephalitis model, T-cell or myeloidspecific Bmal1 deletion mitigates neuroinflammation and neurological impairment (Druzd et al.,
2017; Sutton et al., 2017). In our hands, astrocyte-specific Bmal1 deletion in APP/PS1 mice
induces astrogliosis but has no impact on amyloid plaque deposition (McKee et al., 2022),
suggesting that astrocyte activation due to Bmal1 deletion induces specific cellular adaptations
that suppress intraneuronal tau and α-synuclein aggregation, but not extracellular amyloid-beta
deposition. Accordingly, previous studies have shown that neuronal BAG3 can drive degradation
of tau or α-synuclein (Friedman et al., 2018; Fu et al., 2019; Ji et al., 2019), while no such data
exists for amyloid-beta. Thus, the effects of Bmal1 deletion may be highly cell-type and
pathology specific.
While therapeutic manipulation of BMAL1 in humans may be difficult due to effects on
circadian function, we hypothesize that downstream pathways activated in Bmal1-deficient
astrocytes may offer novel targets. Our data suggest that BAG3 may be such a target. Previous
studies have demonstrated that BAG3 can facilitate degradation of α-syn and tau aggregates in
neurons (Cao et al., 2017; Fu et al., 2019; Ji et al., 2019; Lin et al., 2022), though this had not
been shown in astrocytes. However, astrocytic expression of BAG3 and its partner protein
HSPB8 has been described in post-mortem AD and PD brain (Seidel et al., 2012). We observed
clear increases in BAG3 expression in subclusters of activated astrocytes in humans, suggesting
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that these astrocytes may be attempting to clear protein aggregates. This attempt is clearly
insufficient to prevent disease, perhaps because it occurs too late in the disease course, as BAG3
is only increased in symptomatic AD in human brain (Supplemental Fig. 9). Our data shows that
astrocyte activation with BAG3 induction is most protective prior to protein aggregation,
suggesting that early induction of astrocytic protein degradation machinery, including BAG3,
may be beneficial for preventing disease. Thus, therapies designed to induce protective astrocyte
activation early in disease pathogenesis, via manipulation of BMAL1 or its downstream targets,
may be advantageous for preventing spread of intra-neuronal protein aggregates. In AD, this
might occur when amyloid plaques are present, but before widespread tau pathology is present.
Therapeutic strategies which manipulate astrocyte BMALl1 or BAG3 warrant future testing in
tau and synuclein models.

2.5 Materials and Methods
Mice: All animal experiments were approved by the Washington University IACUC and were
conducted in accordance with AALAC guidelines and under the supervision of the Washington
University Department of Comparative Medicine. CAG-CreERT2, Aldh1l1-CreERT2, CX3CR1ERT2,
Bmal1flox/flox, C57/B6J and hMAPT P301S PS19 Tg mice were all obtained from Jackson Labs
(Bar Harbor, ME) and crossed in our facility at Washington University in St. Louis. In general,
crosses were designed such that Cre+/-;Bmal1f/f males were bred with Bmal1f/f or
Bmal1f/f;P301S+/- females, such that a mix of Cre+ and – littermates were produced for
comparison with each other. Litters from several similar breeding cages were combined in each
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analysis. For experiments with CAG-CreERT2, Aldh1l1-CreERT2 lines, all mice (Cre+ and Crelittermates) were treated with tamoxifen (3mg/day x 5 days) at 2 months of age. All mice were
maintained on a pure C57B6 background except P301S PS19 mice, which are on a mixed
C57B6/C3 background. PS19 mice were bred at least 3 generations with C57B6 mice (in order to
generate PS19 mice with appropriate Cre and floxed alleles), and Cre+ and – littermates were
compared in order to account for any remaining background heterogeneity.
Antibodies: Immunohistochemical antibodies used in this study include: GFAP (rabbit,
Dako/Agilent Z0334, 1:5000), IBA1 (goat, Abcam ab5076, 1:500), CD68 (rat, BioRad
MCA1957, 1:500), AT8b (mouse, ThermoFisher MN1020, 1:500), GFAP conjugated to
Alexafluor-647 (mouse, Cell Signalling Technologies, 3657S, 1:1000), Bmal1 (rabbit, Novus
NB100-2288, 1:2000), MC1 (gift of Dr. Peter Davies, 1:500), BAG3 (rabbit, proteintech 105991-AP, 1:500), biotinylated phospho-alpha-synuclein (mouse, Biolegend 825704, 1:1000).
Immunohistochemistry and imaging: Mice were deeply anesthetized with i.p. pentobarbital
(150mg/kg), then perfused with ice-cold Dulbecco’s modified PBS (DPBS) containing 3 g/l
heparin. For all analysis in the P301S mice; one hemisphere was dissected into regions, flash
frozen, and stored at -80o C for RNA analysis as described below. The other hemisphere was
post-fixed in 4% paraformaldehyde for 24 hours (4°C), then cryoprotected with 30% sucrose in
PBS (4°C) for 24 hours. For all analysis with PFF-injected mice, whole brain was collected, and
fixed in 4% paraformaldehyde for 48 hours (4°C), then cryprotected with 30% sucrose for 48
hours (4°C). Brains were then sectioned on a freezing sliding microtome in 40-micron serial
coronal sections and stored in cryoprotectant solution (30% ethylene glycol, 15% sucrose, 15%
phosphate buffer in ddH20). Sections were washed in TBS x 3, blocked for 60 minutes in TBSX
(TBS+ 0.4% Triton X-100) containing 3% donkey serum, and incubated overnight at 4°C in
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primary antibodies diluted in TBSX containing 1% donkey serum. Sections were then incubated
for 1 hour at room temperature in PBSX (or TBSX with 1:1000 donkey fluorescent secondary
antibody and mounted on slides using Prolong Gold (Invitrogen P36930). For AT8b staining,
sectioned were washed in TBS x 3, then incubated in 0.3% hydrogen peroxide for 10
minutes. Sections were washed again in TBS x 3, then blocked in 3% milk diluted in
TBS+0.25% Triton X-100 for 30 minutes. Sections were incubated overnight in biotinylated
AT8 in TBS + 0.25% Triton X-100 + 1% milk at 4°C. The next day, sections were washed and
then developed using ABC Elite (Vector PK-6100) for 60 minutes. Sections were then incubated
in DAB and dried before coverslipping. ThioS staining: Free floating sections were washed in
TBS x 3, then incubated in 1% Thioflavin-S dissolved in 80% ethanol for 8 minutes. Sections
then rinsed with 80% ethanol for 1 minute x 2, and rinsed with TBS x 3. Sections then mounted
on slides before coverslipping. Microglia branching analysis was done by taking 20x confocal
images of microglia, isolating individual microglia in each image, then the images were
binarized and skeletonized using the ImageJ skeletonize plugin. The particle analysis function
was then used to remove background before using the Analyze Skeleton function in ImageJ to
analyze the number of branches per cell. All branching analysis were done blinded to
genotype. All fluorescent imaging was done on a Zeiss Axioimager Z2 at 10x magnification at
Washington University in St. Louis’s core imaging facility. All confocal microscopy was
performed on a Zeiss LSM700 at 20x magnification. Sections stained with DAB were imaged
on the NanoZoomer digital pathology system. Images taken with the Axioimager Z2 or
Nanozoomer were analyzed in ImageJ. Confocal images were analyzed in Imaris where 3D
reconstructions were made and volume measurements were calculated.
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Tau ELISA: Human tau ELISAs were performed by first fractionating tissue samples. Cortical
brain tissue was weighed and RAB buffer (0.1M MES, 0.5mM MgSO4, 1mM EGTA, 2mM
DTT, 0,75M NaCl, protease/phosphatase inhibitors), pH 6.8 was added at 15ul per mg of
tissue. Tissue was sonicated at 30% amplitude in pulses for 1 minute. Volume in each tube were
standardized and spun in an ultrafuge for 20 min at 50,000xg at 4°C. Remove the supernatant
and store as RAB fraction. The same volume of RIPA buffer (150mM NaCl, 50mM Tris, 0.5%
C24H39O4Na, 1% Triton-100, 0.5% SDS, 25mM EDTA, protease/phosphatase inhibitors), pH 8.0,
was added to the pellet. Samples were then sonicated and run in the ultrafuge as
before. Supernatant was saved as the RIPA fraction. Formic acid was added at 1/3 of the
volume used for RAB and RIPA before being triturated thoroughly and then run once again in
the ultrafugre before taking the supernatant as the formic acid fraction. To run the human tau
ELISA, plates were coated with 20ug/mL of Tau5 (gift from the Holtzman lab) overnight at
4°C. Plates were washed 5x with PBS then blocked with 4% BSA (Fisher BP9700100) in PBS
for an hour at 37°C. Plates were washed 5x before adding diluted sample and tau standard (a gift
from the Holtzman lab) in sample buffer (0.25% BSA in PBS, 300mM Tris pH 7.4, phosphatase
inhibitor), then incubating overnight at 4°C. Formic acid samples were neutralized by diluting
1:20 in 1M Tris, pH 11.0. Plates were washed 8x with PBS before adding biotinylated HT7 at
0.2ug.mL diluted in 1% BSA+PBS and incubated for 1.5 hours at 37°C. Plates were washed 8x
with PBS and then streptavidin poly-HRP40 (Fitzgerald 65R-S104PHRP) diluted 1:4000 in 1%
BSA in PBS was added for 1.5 hours. Plates were washed once more before adding super slow
TMB substrate (Fisher T5569) and reading absorbance 15 minutes later.
RNA quantification: Brain tissue was homogenized in 500ul of Trizol with beads added before
running in a bullet blender for 3 minutes. Cultured cells were collected and homogenized by
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adding 500ul TRIzol/well of a 12-well plate directly to plated cells. TRIzol samples were then
subjected to chloroform extraction (1:6 chloroform:TRIzol, followed by thorough mixing,
centrifugation at 12500 x g for 15 minutes). RNA was then extracted from the aqueous layer
using the PureLink RNA Mini Kit according to manufacturer’s instructions. RNA concentration
was measured on a Nanodrop spectrophotometer, then cDNA was made using a high capacity
RNA-cDNA reverse transcription kit (Applied Biosystems/Life Technologies) with 250ng-1 μg
RNA per 20μL reaction. Real-time quantitative PCR was performed with ABI TaqMan primers
and ABI PCR Master Mix buffer on ABI StepOnePLus or QuantStudio 12k thermocyclers.
Taqman primers (Life Technologies) were used, and mRNA measurements were normalized to
β-actin (Actb) mRNA for analysis. For larger experiments, microfluidic qPCR array
measurements were performed by the Washington University Genome Technology Access
Center using a Fluidigm Biomark HD system, again using Taqman primers. RNA sequencing
was performed and values normalized as previously described (McKee et al., 2022); GEO
accession number is pending and raw data is available at Musieklab/org. Volcano plot was made
using Enhanced Volcano R packaged and heatmap was made using the Pretty Heatmap
package. GO pathways were generated using Metascape.org.
Primary mouse astrocyte culture: Primary mouse astrocyte cultures were prepared as previously
described (Lananna et al., 2018). Briefly, P2 mouse pups brains were isolated in cold DMEM,
the meninges removed, and the cortices dissected. Cortices were then incubated in 0.025%
tryspin solution (Gibco) at 37°C for 15 minutes, then triturated using a glass pipet before adding
to a T75 flask. Once cells reached confluency, cells were plated in 24 well plates at 70,000 cells
per well.
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Stereotactic injections: Mice were anesthetized with isoflurane and stereotactically injected with
2ul (approximately 4ug of PFFs) into the left dorsal striatum using a Hamilton microsyringe
attached to a motorized injector (Stoelting). Coordinates used were: 0.2mm anterior, 2.0mm
lateral to bregma, and 3.2mm ventral to the surface of the skull.
siRNA transfections: Primary mouse astrocyte-enriched cultures were transfected with siRNA
using lipofectamine RNAiMAX (Life Technologies) in Optimem (Life Technologies) per
manufacturer’s instructions 24-48 hours after replating. 48 hours after transfection, media was
changed to DMEM plus 10% FBS and 1% penicillin/streptomycin. SiRNAs targeting mouse
Bmal1, Bag3 and Scr (non-targeting, targeting no known mouse gene) were obtained from
Horizon Discovery/Dharmacon (Lafayette, CO). ON-TARGETplus SmartPool siRNA was used,
which contains 5 separate siRNAs targeting the gene of interest which are pooled together,
Bmal1 (product L040483-01-005), non-targeting (control or “scrambled”) )D-001210-01-05),
and Bag3 (product L-064450-00-0005). An siRNA:RNAiMAX ratio of 1:1.25) was used, and 40
pmol of siRNA (2uL of 20uM stock) was added to each well in a 24-well plate for 24 hours
before replacing with astrocyte media.
Viral vectors: Bag3 overexpression was made at the Hope Center Viral Vector core using
Mammalian Gene Collection cDNA for mouse BAG3 (Enztrez ID 29810) purchased from
Horizon Discovery (Lafayette, CO; Cat #: MMM1013-211692359). Bag3 cDNA was then
packaged into an AAV2/8 envelope under expression of a GFAP promoter. An HA tag was also
included as a marker of Bag3 expression.
Phagocytosis Assay: Confluent astrocytes were plated at 70,000 cells per well in a 24 well
plate. The next day, siRNA was added and then removed the following day. For viral
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expression, virus was added at 1x1011 GC/mL. Three days after addition of virus or siRNA,
phrodo-PFFs were added at 2.5ug/mL in astrocyte media for three hours. Cells were then
washed once with 1x PBS, and then astrocyte media was added back to the cells. 24 hours after
phrodo-PFFs were removed, cells were trypsinized, washed twice with flow buffer, then
resuspended and run on a MACSQuant VYB flow cytometer. Data was then analyzed in
FlowJo.
αSyn PFF preparation and injection (Gus): Purification of recombinant mouse sequence αSyn
monomer and in vitro fibril assembly were performed as described (Volpicelli-Daley et al.,
2014) with minor modifications. Fibril assembly reactions were carried out in an Eppendorf
ThermoMixer at 1000 rpm for 7 days. An aliquot of the resulting suspension was centrifuged at
15,000g for 20 min, and the PFF concentration was estimated by subtracting the concentration of
αSyn monomer in the resulting supernatant from the starting monomer concentration. PFFs were
aliquoted and stored at −80°C until use. Before use, aliquots were thawed and sonicated briefly
in a water bath sonicator (Qsonica). To generate αSyn PFFs conjugated to pHrodo Red, αSyn
monomer was labeled with pHrodo Red using a succinimidyl ester reagent (ThermoFisher
P36600) according to the manufacturer’s instructions, and αSyn PFFs were prepared as above
using an excess of unlabeled monomer at a molar ratio of 1:20.

Statistics: Statistical test included student T test and one-way ANOVA, both performed with
Graphpad software. One way ANOVA was performed with Tukey correction for multiple
comparisons.
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Human Astrocytes single-nucleus RNA-seq: We used fresh frozen parietal cortex of postmortem
brains from the Neuropathology Cores of the Charles F. and Joanne Knight Alzheimer’s Disease
Research Center (Knight-ADRC) and the Dominantly Inherited Alzheimer Network (DIAN).
These samples were obtained with informed consent for research use and were approved by the
review board of Washington University in St. Louis. AD neuropathological changes were
assessed according to the criteria of the National Institute on Aging-Alzheimer’s Association
(NIA-AA). Their demographic, clinical severity, and neuropathological information are
presented in Brase L et al (Brase et al., 2021). Nuclei was extracted from fresh frozen brain
regions (~200-400mg of tissue) following the same protocol, as reported in Del Aguila et al
(Del-Aguila et al., 2019) and Benitez BA (dx.doi.org/10.17504/protocols.io.2a5gag6). 10X
genomic library preparation: Nuclei was processed using the 10x Genomics Chromium
Controller and the Chromium Next Gem Single Cell 10x 3' Library & Gel Bead Kit v3.1 (PN
1000121) following the standard manufacturer's protocols (10X Genomics). Samples were
sequenced on the Illumina NovaSeq S4 (200 cycles), targeting 50,000 reads/cell (2 × 150 pairedend reads). Sequencing alignment: We employed the 10X CellRanger 6.0 pipeline to perform
transcript alignment (human genome build GRCh38), counting, and inter-library normalization.
Quality control for nucleus inclusion: We followed the Seurat v4 protocol to clean the snRNAseq data. Each raw gene expression matrix for each sample was plotted, using
BarcodeInflectionsPlot to calculate the inflection points derived from the barcode-rank
distribution. Once the thresholds were determined, a subset of the data was isolated. We removed
nuclei with high mitochondria gene expression following a previously proposed dynamic model.
Briefly, the nuclei were grouped by their percentage of mitochondria values using k = 2
clustering and the group with the higher percentage values was removed. Genes that were not
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expressed in at least 10 nuclei were removed from the final matrix. To detect and discard
doublets, we used Doublet Finder, which removes nuclei with expression profiles that resemble
synthetically mixed nuclei from the dataset. The gene expression matrices from all samples were
combined in R for further processing using the Seurat protocol. The expression matrix was
normalized using the SCtransform protocol by Seurat. We regressed, during the normalization,
against number of Genes, number of UMI and the percentage of mitochondria. The principal
components (PC) were calculated using the first 3,000 variable genes and the Uniform Manifold
Approximation and Projection (UMAP) analysis was performed with the top 14 PCs. Clustering
and visualization: We will cluster nuclei using a graph-based clustering approach implemented
in the Seurat package (v4). Cell-type annotation and sub-clustering: For each pre-cluster, we will
assign a major brain cell-type label evaluating the enrichment for sets of marker genes for
neurons, astrocytes, oligodendrocytes, microglia, oligodendrocyte precursor cells, and
endothelial cells, as we previously published (Brase et al). We employed the following markers
RYR3, LRRC16A, F3, ETNPPL, CLU, SLC1A2, GJA1, DIO2, SLC4A4, EDNRB, AQP4,
GPR37L1, CPE, ATP1B2 and SLCO1C1 for astrocytes. Cell-type/-subtype differentially
expressed genes (DEG): We identified sub-cluster up/down expressed genes for each cell type to
characterize the genes, pathways, and biological processes. We used traditional regression
methods (Monocle3 package). We then employed Seurat’s FindNeighbors and FindClusters
functions to identify unique cell states or subclusters (resolution=0.1, 0.2, 0.2, 0.05, 0.15).
Additionally, we used the Garnett protocol to examine nuclei in each expression state within
each cell type to detect and remove those nuclei that did not resemble a trustworthy expression
profile from downstream analyses.

64

BAG3 and ARNTL expression in brain tissue
Data from gene expression from AD and controls was accessed via GEO database
(https://www.ncbi.nlm.nih.gov/geo/) (GEO accession number GSE44772; see also accession
numbers GSE44768 - cerebellum (CB), GSE44770 - dorsolateral prefrontal cortex (PFC) BA9,
and GSE44771 - visual cortex (VC) BA17). PFC is commonly affected in LOAD, whereas VC
and CB remain less affected throughout most of the disease progression. These were composed
of 129 LOAD patients and 101 nondemented subjects. We performed the comparisons using the
GEO2R web tool from NCBI (https://www.ncbi.nlm.nih.gov/geo/geo2r/.)

Chapter 3: Deletion of the circadian clock
gene Bmal1 induces cell-autonomous
dopaminergic neurodegeneration
3.1 Abstract
Circadian rhythm dysfunction is a hallmark of Parkinson Disease (PD), and diminished
expression of the core clock gene Bmal1 has been described in PD patients. BMAL1 is required
for core circadian clock function, but also serves non-rhythmic functions. Bmal1 deletion can
cause brain oxidative stress and synapse loss in mice, and can exacerbate dopaminergic
neurodegeneration in response to MPTP. Here we examined the impact of cell type-specific
Bmal1 deletion on dopaminergic neuron viability in vivo. We observed Global, post-natal
deletion of Bmal1 caused loss of tyrosine hydroxylase-positive (TH+) dopaminergic neurons in
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the substantia nigra pars compacta (SNpc). This was not due to disruption of behavioral
circadian rhythms, and was not induced by astrocyte- or microglia-specific Bmal1 deletion.
However, either pan-neuronal or TH neuron-specific Bmal1 deletion caused cell-autonomous
loss of TH+ neurons in the SNpc. Finally, global Bmal1 deletion exacerbated TH+ neuron loss
following injection of alpha-synclein fibrils. Transcriptomic analysis of neuron-specific Bmal1
KO brain revealed dysregulation of pathways involved in oxidative phosphorylation and
Parkinson Disease. These findings demonstrate a cell-autonomous role from BMAL1 in
regulating dopaminergic neuronal survival, and may have important implications for
neuroprotection in PD.

3.2 Introduction
Circadian clocks regulate many aspects of cellular function, including cellular
metabolism, redox homeostasis, and inflammation (Hood & Amir, 2017; Musiek & Holtzman,
2016). On a molecular level, the core circadian clock consists of a transcriptional-translational
feedback loop which tunes gene expression and cellular function to a 24-hour rhythm. This core
circadian clock consists of the basic helix-loop-helix transcription factor BMAL1 (aka ARNTL),
which heterodimerizes with CLOCK or NPAS2 to drive tissue-specific transcriptional programs.
BMAL1 drives expression of several negative feedback repressors, including PER, CRY, and
REV-ERB proteins, which in turn inhibit BMAL1-mediated transcription and are tuned through
post-transcriptional regulation to a 24-hour period (Mohawk, Green, & Takahashi, 2012).
BMAL1 is required for circadian oscillations in transcription, cellular function, and behavior,
and Bmal1 deletion renders mice arrhythmic at both cellular and behavioral levels (Bunger et al.,
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2013). While binding of BMAL1 to DNA is highly rhythmic, BMAL1 also regulates expression
of many non-rhythmic transcripts, and is thus thought to exert additional “non-circadian”
functions. Our group has previously shown that Bmal1 deletion causes astrogliosis, oxidative
stress, and synapse loss in mouse cerebral cortex (Lananna et al., 2018; Musiek et al., 2013).
However, overt neurodegeneration was not observed in Bmal1 KO mice in vivo in regions such
as the hippocampus, cortex, and striatum. Furthermore, Bmal1 deletion appears to have
protective effects in some models of neurological disease, such as stroke and spinal cord injury
(Lembach, Stahr, Ali, Ingenwerth, & von Gall, 2018; Slomnicki et al., 2020). Thus, the role of
Bmal1 in neuronal health and neurodegeneration is not entirely understood.
Parkinson Disease (PD) is a common neurodegenerative disease characterized clinically
by progressive tremor, rigidity, bradykinesia, postural instability, autonomic dysfunction, and
neuropsychiatric symptoms. Key pathological hallmarks of PD include degeneration of
dopaminergic neurons in the substantia nigra pars compacta (SNpc), as well as intraneuronal
aggregation of alpha-synuclein (αSyn) in Lewy bodies and Lewy neurites. A considerable
literature describes circadian disruption in PD, including fragmentation of daily behavioral
rhythms and suppression of core circadian clock gene expression in peripheral blood
mononuclear cells from PD patients, including blunting of rhythms of Bmal1 (Breen et al., 2014;
Cai, Liu, Sothern, Xu, & Chan, 2010; Videnovic & Golombek, 2013; Videnovic et al., 2014). In
mice, either light-induced circadian disruption (Lauretti, Di Meco, Merali, & Praticò, 2017), or
germ-line Bmal1 deletion, have been shown to exacerbate dopaminergic neurodegeneration
caused by the mitochondrial toxin 1-methyl-4-phenyl-1, 2, 4, 5- tetrahydropyridine (MPTP).
While a previous study implicates microglial dysfunction as critical to this phenotype, germ-line
Bmal1 KO mice exhibit a variety of developmental phenotypes that could contribute, and true
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cell type-specific analysis in vivo has not been conducted. Here, we examine the effects of postnatal and cell type-specific Bmal1 deletion on basal survival of dopaminergic neurons in the
SNpc and test a physiologically-relevant model of αSyn pathology and neurodegeneration. Our
data indicate that Bmal1 regulates specific cell-autonomous transcriptional programs in
dopaminergic neurons which are critical for their survival, suggesting that preserving Bmal1
expression may be neuroprotective in PD.

3.3 Results
3.3.1 Global and brain-specific Bmal1 deletion induces degeneration of
dopaminergic neurons
We first examined the dopaminergic neuronal health in a model of tamoxifen-inducible
global Bmal1 deletion (CAG-CreERT2;Bmal1f/f). We and others have thoroughly characterized this
mouse elsewhere, and shown that post-natal tamoxifen treatment causes widespread Bmal1
deletion in the brain as well as behavioral arrhythmicity, but eliminates a variety of
developmental pathologies noted in germ-line Bmal1 KO mice (Kress et al., 2018; Yang et al.,
2016). We used stereology to count tyrosine hydroxylase positive (TH+) neurons in the
substantia nigra pars compacta (SNpc), the region of most pronounced dopaminergic
neurodegeneration in PD, in Cre- (control) and Cre+ (global Bmal1 KO) littermates, all treated
with tamoxifen. Two months after the completion of tamoxifen treatment, a spontaneous,
significant decrease in TH+ neurons was observed in Cre+ mice (Fig. 3.1A-C). We also
examined the ventral tegmental area (VTA), which is an adjacent brain region primarily
containing dopamine cells that does not degenerate as consistently in PD. To our surprise, TH+
neurons were found to be significantly reduced in the VTA (Fig. 3.1F,G), suggesting a pan68
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VTA

Figure 3.1. Global and brain-specific Bmal1 deletion induces degeneration of dopaminergic
neurons. (A) Representative epifluorescent images (10X) of TH and NeuN staining within the
SNpc of Cre-;Bmal1f/f control (CAG-Cre-) and CAG-Cre+;Bmal1f/f global Bmal1 KO mice
(CAG-Cre+). (B) Stereological counts of TH+ cells in the SNpc of CAG-Cre- controls and CAGCre+ Bmal1 KO mice. n= 5-6 mice per genotype. (C) Quantification of NeuN+ cells in the SNpc
on Cre- controls and CAG-Cre+ Bmal1 KO mice. n=5-6 mice per genotype, four sections per
mouse. (D) Representative images (10X) of SNpc TH staining in the SNpc of Nestin-Cre-;
Bmal1f/f control (Nes Cre-) and Nestin-Cre+;Bmal1f/f brain-specific Bmal1 KO mice. (E)
Stereological counts of TH+ cells in the SNpc and Nestin-Cre- control (Nes Cre-) and NestinCre+ brain-specific Bmal1 KO mice (Nes Cre+). n= 5 mice per genotype. (F) Representative 10x
images of TH-DAB stained SNpc with (G) quantification of the number of dopaminergic
neurons in the VTA region.

sensitivity of TH+ neurons to the global deletion of Bmal1. However, we detected no loss of
neuronal nuclei in the hippocampus of global KO mice, suggesting some selectivity of
neurodegeneration (Fig. 3.2A,B). To ensure that our findings in the SNpc did not represent a
downregulation of TH gene/protein expression (as opposed to neuronal death), we found that
NeuN+ neurons in the SNpc also decreased in Cre+ mice to a similar degree at TH+ cells,
suggesting neurodegeneration rather than TH protein downregulation (Fig. 3.1B). CAGCreERT2+;Bmal1f/f mice which were not treated with tamoxifen showed no change in TH+ neurons
in the SNpc, demonstrating that Cre expression alone was not the cause of toxicity (Fig. 3.2C,D).
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Figure 3.2. Global Bmal1 deletion does not impact hippocampal neurons nor is there
Cre toxicity. (A) Representative 10x images of the hippocampus using the same CAG-Cre mice
as in Fig 3.1 with (B) quantification of NeuN-positive particles in the hippocampus. (C) A cohort
of CAG-Cre mice without tamoxifen stained with TH-DAB and Cresyl violet in the SNpc with
(D) quantification of total TH particles.

Global inducible Bmal1 KO mice are behaviorally arrhythmic under constant conditions
and have Bmal1 deletion in all tissue of the body (Kress et al., 2018; Yang et al., 2016). In order
to determine if disrupted behavioral rhythms or peripheral Bmal1 deletion contributed to TH+
neuron loss, we examined the SNpc of Nestin-Cre+;Bmal1f/f mice, which have deletion of Bmal1
in neurons, astrocytes, and other cells throughout the brain but have intact Bmal1 expression in
peripheral organs, as well as intact behavioral rhythms due to conserved Bmal1 expression in the
SCN (Kress et al., 2018; Musiek et al., 2013). Nestin-Bmal1 KO mice also exhibited pronounced
loss of TH+ neurons in the SNpc (Fig. 3.1D,E), demonstrating that degeneration is likely due to
loss of Bmal1 expression in neurons or astrocytes, and not due to disrupted behavioral circadian
rhythms or peripheral organ dysfunction. Notably, Nestin-Bmal1 KO mice also have intact
microglial Bmal1 expression, indicating that microglial Bmal1 loss does not account for the TH
neurodegeneration phenotype.
In order to further investigate the role of circadian rhythm dysfunction in dopaminergic
neurodegeneration, we induced circadian desynchrony in 3 month old wild type C57Bl/6 mice
via 3 months of exposure to a 10 hour light:10 hour dark cycle, while controls were kept on
standard 12h:12h LD lighting(Karatsoreos, Bhagat, Bloss, Morrison, & McEwen, 2011). This
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intervention had no impact on TH+ neuron counts in the SNpc (Fig. 3.3A,B), suggesting that loss
of Bmal1 function, not rhythm disturbance, is critical for the phenotype.
We have previously shown that mice with astrocyte-specific Bmal1 deletion (Aldh1l1CreERT2;Bmal1f/f) develop spontaneous astrogliosis and astroglial transcriptional alterations
(Lananna et al., 2018). To evaluate a role for astrocyte Bmal1 in dopaminergic cell loss, we next
examined TH+ neurons in the SNpc in these inducible astrocyte-specific Bmal1 KO mice. One
month after tamoxifen treatment, astrocyte Bmal1 KO mice showed no change in TH+ neuron
counts in the SNpc, as compared to Cre- littermate controls (Fig. 3.3C,D). Thus, astrocyte Bmal1
deletion does not explain the TH+ neuron loss phenotype observed in either Nestin-Bmal1 KO or
CAG-Bmal1 KO mice.

3.3.2 Neuron-specific Bmal1 deletion induces dopaminergic neuron loss and
dysregulation of genes involved in Parkinson’s Disease and oxidative
phosphorylation

Next, we examined SNpc TH+ neuron counts in mice with pan-neuronal Bmal1 deletion.
These BAC-transgenic CaMK2a-Cre; Bmal1f/f mice were previously shown to have widespread
neuronal Bmal1 deletion causing behavioral rhythm disturbances(Izumo et al., 2014; Lananna et
al., 2018). Both 4mo and 10mo CaMK2a-Cre; Bmal1f/f mice exhibited decreased SNpc TH+
neuron counts, as compared to Cre- littermate controls (Fig. 3.4A,B), demonstrating a neuronal
cell-autonomous effect of Bmal1 deletion on TH+ cell survival. In order to examine possible
transcriptional mechanisms by which Bmal1 deletion might influence neuronal survival, we
performed bulk RNAseq on cortical tissue from 4mo CaMK2a-Cre; Bmal1f/f mice and Cre-
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Figure 3.3. Circadian misalignment and astrocyte-specific Bmal1 deletion does not impact
dopaminergic cell numbers in the SNpc. (A) Representative images (10x) of TH DAB and
cresyl violet staining in 4 month old mice subjected to a 10:10 or 12:12 lighting schedule from
age 3mo to 6 mo. (B) Stereological counts of TH+ cells within the SNpc. n=4-6 mice per group.
ns, not significant by two-tailed t test. ns, not significant.

littermate controls (Fig. 3.5A-C). Utilizing differential expression analysis, we identified 634
dysregulated genes (p-value < 0.05). Among those most strongly downregulated were the known
BMAL1 transcriptional targets Nr1d1 and Nr1d2 (REV-ERBα and β), Dbp, Per3, and Ciart
/CHRONO (Fig. 3.4C). Notably, the number of differentially-expressed genes was substantially
lower than we have previously seen in global Bmal1 KO mice, and astrocyte-specific BMAL1
target transcripts such as Chi3l1, which is differentially expressed in global KOs (Lananna et al.,
2020), were unchanged in the Camk2a-Bmal1 KO mice. Thus, the transcriptome appears quite
specific for neuronal Bmal1 deletion. KEGG pathway gene set enrichment analysis (GSEA) was
then performed on the most differentially expressed genes in this dataset, which identified
Parkinson’s disease and Oxidative Phosphorylation as two of the top five pathways (Fig. 3.5B).
Examination of specific transcripts involved in this GSEA showed significant overlap of
dysregulated genes between the Parkinson’s disease and Oxidative Phosphorylation pathways,
suggesting that Bmal1 deletion largely impacts genes that are shared between these pathways
(Fig. 3.5C).
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Figure 3.4. Neuron-specific Bmal1 deletion induces dopaminergic neuron loss. (A)
Representative images (10x) of TH and cresyl violet staining in the SNpc of Cre-;Bmalf/f control
and Camk2a-iCre;Bmalf/f neuron-specific Bmal1 KO mice. (B) Stereological counts of TH+ cells
within the SNpc of 4 and 10 month cohorts of Cre- control and Cre+ neuron-specific Bmal1 KO
mice. n=3-4 mice per group. (C) A. Quantification of circadian gene expression within cortical
tissue of BKO and WT mice. Data represented as a fold change. ***P < 0.001 by two-way
ANOVA with a multiple comparisons post test.
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Figure 3.5. Neuron-specific Bmal1 deletion induces dysregulation of genes involved in
Parkinson Disease and oxidative phosphorylation. (A) Volcano plot showing differentially
expressed genes (DEGs) in cortex tissue of Camk2a-iCre;Bmalf/f neuron-specific Bmal1 KO
mice. DEGs with fold change > 2 and uncorrected p value <0.01 are shown in red. (B) KEGG
pathway gene set enrichment analysis of DEGs in of Camk2a-iCre;Bmalf/f neuron-specific Bmal1
KO mice. (C) Cluster profiler of Camk2a-iCre;Bmalf/f mice illustrating genes associated with
KEGG pathways.

3.3.3 Tyrosine hydroxylase-specific Bmal1 deletion induces dopaminergic
neuron degeneration and increased microgliosis
Finally, we sought to determine if deletion of Bmal1 specifically in TH+ neurons was
sufficient to induce degeneration. Accordingly, we generated TH-Cre; Bmal1f/f mice to drive
Bmal1 deletion exclusively in TH+ cells. Of note, the BMAL1 antibody gives some non-specific
nuclear signal which we have observed in germ-line Bmal1 KO mice, limiting the quantification
of BMAL1 deletion in TH+ cells. Despite this, we confirmed by confocal imaging that Bmal1
intensity was decreased in the SNpc and was visually weaker in TH+ cell nuclei (Fig. 3.6A,B),
indicating deletion within TH+ neurons of the SNpc. Stereological counting revealed that THBmal1 KO mice showed a significant reduction of TH+ neurons in the SNpc, as compared to
Cre- controls, demonstrating that Bmal1 exerts cell-autonomous effects on dopaminergic neuron
survival in vivo (Fig. 3.6C). Because Bmal1-deficient TH+ neurons are presumably vulnerable to
death, our analysis of BMAL1 expression in persisting TH+ neurons likely underestimates the
degree of Bmal1 deletion in this cell population. Upon further analysis, we also found a
significant decrease in Iba1+ microglia branching within the SNpc in Cre+ mice (Fig. 3.6D,E),
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Figure 3.6. Tyrosine Hydroxylase-specific Bmal1 deletion induces dopaminergic neuron
degeneration and increased microgliosis. (A) Representative images (10x) of TH and BMAL1
staining in the SNpc of Cre-;Bmalf/f control and TH-Cre;Bmalf/f TH-specific Bmal1 KO mice. (B)
Quantification of BMAL1 immunofluorescent intensity within the SNpc of Cre- control and
Cre+ TH-specific Bmal1 KO mice. n=6 mice per genotype. (C) Stereological counts of TH+
cells within the SNpc of Cre- control and Cre+ TH-specific Bmal1 KO mice. n=6 mice per
genotype. (D) Representative images (20x) of TH+ neurons (red) and microglia (Iba1, green)
within the SNpc of Cre- control and Cre+ TH-specific Bmal1 KO mice. Representative
skeletonized microglia reconstructions from each genotype are shown in the right panels. (E)
Quantification of average branches per microglial cell within the SNpc of Cre- control and Cre+
TH-specific Bmal1 KO mice. n=6 mice per genotype, five images per mouse, n=10 microglia per
mouse.

suggesting increased microglial activation (due to amoeboid microglial morphology with less
branching) around the site of TH+ neurodegeneration. Microgliosis was not observed in the
hippocampus of Cre+ mice (Fig. 3.7A-C), suggesting a region specific effect.

3.3.4 Alpha-synuclein injected Global Bmal1 KO mice exhibit increased
sensitivity to dopaminergic neuron degeneration
A previous study showed that germline Bmal1 deletion can exacerbate dopaminergic
neuron loss caused by the mitochondrial complex I inhibitor MPTP (Wen-wen, Shi-zhuang,
Guo-dong, & Lu-bing, n.d.). In order to build upon our current observation and extend these
findings to a more
80

A.
B.

C.

Figure 3.7. Tyrosine Hydroxylase-specific Bmal1 KO mice exhibit no changes in
hippocampal microgliosis. (A) Representative images (10x) of IBA1, and CD68 staining in 2-3
month old WT and KO mouse hippocampus. (B) Quantification of IBA1 staining. n=6 mice per
genotype. (C) Quantification of CD68 staining. n=6 mice per genotype. ns, not significant by
two-tailed t test.

disease-relevant PD model, we examined TH+ neuron survival in CAG-Bmal1 KO mice
subjected to intrastriatal injection of alpha-synuclein preformed fibrils (a-syn PFFs). In this
model, exogenous a-syn PFFs are injected into the striatum and are transported in a retrograde
manner to the SNpc, where they induce misfolding of endogenous alpha-synuclein and cause
TH+ neuronal death (Luk et al., 2012; Paumier et al., 2015). We treated mice with tamoxifen at
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Figure 3.8. Phosphorylated alpha-synulcein injected Global Bmal1 KO mice exhibit
increased sensitivity to dopaminergic neuron degeneration. (A) Representative images (10x)
of TH and phospho-α-synuclein (P-syn) staining SNpc of Cre-;Bmal1f/f control (CAG-Cre-) and
CAG-Cre+;Bmal1f/f global Bmal1 KO mice (CAG-Cre+) 3mos. after unilateral striatal injection
of α-synuclein PFFs. (B) Quantification of TH+ particles within the ipsilateral and contralateral
SNpc of the mice in A. n=7-8 mice per genotype, four images per mouse. Hatched bars and
black diamonds indicate side ipsilateral to PFF injection. (C) Quantification of P-syn staining in
the SNpc of the mice in A. n=7-8 mice per genotype, two images per mouse. Hatched bars and
black diamonds indicate side ipsilateral to PFF injection.

age 2mo, injected a-syn PFFs into the right striatum at 3mo, and harvested mice at 6mo.
Synuclein PFF injection caused a significant loss of TH+ neurons in the ipsilateral SNpc of Crecontrol mice, and a significantly greater loss of TH+ neurons in Cre+ mice (Fig. 3.8A,B),
demonstrating that global post-natal Bmal1 deletion can exacerbate TH+ neurodegeneration in
response to alpha-synuclein pathology. No difference in phospho-synuclein staining was
observed in between genotypes (Fig. 3.8C). To confirm that this phenotype is mediated by
neuronal Bmal1 expression, we employed the same a-syn PFF model using microglia specific
Bmal1 KO mice (Cx3cr1-CreERT2; Bmal1f/f). Microglia-specific KO mice showed no difference
in TH+ cell number or phospho-synuclein staining between genotypes (Fig. 3.9A-C), further
supporting a cell-autonomous effect of neuronal Bmal1 on dopaminergic neurodegeneration.
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Figure 3.9. Microglia-specific Bmal1 deletion does not exacerbate dopaminergic neuron loss
after alpha-synuclein injection. (A) Representative images (10x) of TH and P-syn staining of
the ipsilateral and contralateral SNpc of Cre-;Bmal1f/f control (Cx3cr1-Cre-) and Cx3cr1CreERT2+;Bmal1f/f microglial Bmal1 KO mice (Cx3cr1-Cre+) 3mos. after unilateral striatal
injection of α-synuclein PFFs. (B) Quantification of TH+ particles in the ipsilateral and
contralateral SNpc of Cre- control and Cx3cr1-Cre+ microglia-specific Bmal1 KO mice from D.
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n=6-8 mice per genotype. Hatched bars and black diamonds indicate side ipsilateral to PFF
injection. (C) Quantification of P-syn staining (% area) in the SNpc of the mice in D. n=6-8 mice
per genotype, two images per mouse. Hatched bars and black diamonds indicate side ipsilateral
to PFF injection.

2.4 Discussion
Our data demonstrate that the circadian clock transcription factor BMAL1 plays a
critical, cell-autonomous role in regulating dopaminergic neuron viability in the SNpc. This
effect appears to be independent of changes in whole-animal circadian rhythms and of gliaspecific Bmal1 expression. Neuronal BMAL1 regulates transcriptional pathways related to
Parkinson Disease and oxidative phosphorylation, and in addition to causing spontaneous death
of a portion of TH+ neurons, also sensitizes TH+ neurons to cell death caused by αSyn PFFs.
Our findings reveal BMAL1 as a novel contributor to dopaminergic neuron survival, and suggest
that environmental or disease states which reduce BMAL1 expression might trigger or
exacerbate neurodegeneration and parkinsonian phenotypes.
Previous reports have demonstrated that both altered 24h light cycle (Lauretti et al.,
2017) and global germ-line Bmal1 deletion can exacerbate TH+ neuronal loss in the SNpc in
response to the mitochondrial toxin MPTP. Our findings generally support these observations
and expand upon them by using multiple cell and tissue-specific Bmal1 knockout mice and an
αSyn PFF-induced pathology model. Loss of microglial Bmal1 was implicated as the
mechanism of degeneration in one of these studies, based on cell culture experiments. However,
our data showing TH+ neuron loss in Nestin-Bmal1 KO mice (which spares microglial Bmal1
expression), as well as our observation that microglia-specific Bmal1 deletion did not alter either
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basal or αSyn PFF-induced TH+ neuronal loss (Fig. 4) indicates that microglial Bmal1 does not
drive the neurodegeneration phenotype, at least in our models. Astrocyte-specific Bmal1 deletion
can cause astrogliosis (Lananna et al., 2018), but deletion of Bmal1 in astrocytes also had no
effect on dopaminergic neuronal survival in our experiments. Moreover, we did not observe loss
of TH+ neurons after 3 months of circadian desynchrony. Because numerous light-based
circadian desynchrony models exist, each with potentially unique effects, further study is needed
to understand the effect of altered light cycles on dopaminergic neurodegeneration. However, our
data point strongly to neuronal loss of Bmal1 as being fundamental to this phenotype,
independent of changes in behavioral circadian function.
Our findings build on previous studies from our laboratory suggesting that BMAL1 plays
a role in neuronal redox homeostasis. Global Bmal1 KO mouse cortex shows increased lipid
peroxidation and impaired circadian expression of redox defense transcripts such as Nqo1 and
Aldh2 (Musiek et al., 2013) as well as diminished expression of several glutathione-s-transferase
transcripts (Lananna et al., 2018). While the RNAseq data in our study was not derived
specifically from TH+ neurons from the SNpc, our analysis shows that Bmal1 regulates
transcripts related to PD pathogenesis and oxidative phosphorylation in cortical neurons in vivo.
Dopaminergic neurons of the SNpc are uniquely sensitive to oxidative stress and mitochondrial
dysfunction, which may explain why neuronal loss was noted in the SNpc but not in the
hippocampus or other regions in Bmal1 KO mice. Accordingly, we previously demonstrated that
while Bmal1-deficient cortical neuron cultures were sensitized to hydrogen peroxide-induced cell
death, global Bmal1 deletion did not impact basal neuronal survival in the cortex and striatum in
vivo. However, hemizygous deletion of Bmal1 sensitized striatal neurons to death induced by the
mitochondrial toxin 3-nitropropionic acid (Musiek et al., 2013). Thus, Bmal1 deletion may
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render all neurons more vulnerable to oxidative stress, which could specifically manifest as TH
neuron loss.
Our findings emphasize that the effects of BMAL1 in neurological disease models are
highly cell type and context dependent. Global Bmal1 deletion can cause brain oxidative stress
and synapse loss (Musiek et al., 2013), exacerbate MPTP-induced dopaminergic neuron loss,
accelerate amyloid plaque formation (Kress et al., 2018), and lower seizure threshold (Gerstner
et al., 2014; Wu et al., 2021), but can conversely mitigate stroke severity(Lembach et al., 2018)
and spinal cord injury (Slomnicki et al., 2020). Bmal1 deletion specifically in astrocytes induces
astrogliosis (Lananna et al., 2018), while deletion in microglia appears to reduce inflammatory
activation(Ni et al., 2019). Deletion of Bmal1 in either lymphocytes or myeloid cells can also
reduce disease severity in the experimental autoimmune encephalomyelitis (EAE) model of
multiple sclerosis (Druzd et al., 2017; Sutton et al., 2017). Our findings here and previously
consistently suggest that loss of neuronal Bmal1 sensitizes neurons to oxidative stress and death,
while Bmal1 deletion in inflammatory cells, including glia, may have more variable (and often
protective) effects. Further study into the cell- and model- dependent effects of Bmal1 and other
clock genes is needed to fully understand how core clock disruption may influence
neurodegenerative diseases.
Sleep and circadian disturbances are common in synucleinopathies including PD. Several
human studies show alterations in the expression of clock gene transcripts in peripheral blood
mononuclear cells (PBMCs) from PD patients. Bmal1 transcript levels in peripheral blood
mononuclear cells were suppressed in human PD patients in two studies (Cai et al., 2010; Li et
al., 2021), while the rhythmic Bmal1 expression was blunted in PD patients in another (Breen et
al., 2014). While it is unknown how peripheral blood and SNpc Bmal1 expression are correlated
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in PD patients, our studies suggest that environmental factors and disease processes which
impact circadian gene expression in the brain, in particular those that lead to suppressed Bmal1
expression, could put dopaminergic neurons at risk of death. Conversely, therapies which
augment Bmal1 expression might be expected to protect TH+ neurons, and this possibility
warrants future investigation.
In summary, the circadian clock gene Bmal1 exerts cell-autonomous effects on
dopaminergic neuronal survival under basal conditions and in response to alpha-synuclein
aggregation. These effects are not phenocopied by light-induced circadian desynchrony or by
glial Bmal1 deletion. Our results provide new insights into the relationship between the neuronal
circadian clock and PD pathogenesis.

2.5 Materials and Methods
Mice: All mouse experiments were carried out according to protocols approved by the
Washington University IACUC. Bmal1(f/f), CAG-CreERT2, TH-Cre, Aldh1l1-CreERT2, Cx3cr1CreERT2 and Nestin-Cre mice were all originally obtained from Jackson Labs (Bar Harbor, ME),
and were crossed in our colony. CaMK2a-Cre;Bmal1f/f were previously described (Izumo et al.,
2014) and fixed/frozen tissue was sent to Washington University for analysis. All mice were
maintained on a pure C57Bl/6 background. All CreERT2 lines were treated with tamoxifen
(Sigma) at 2 months of age. Mice were given daily intraperitoneal of tamoxifen in corn oil at a
dose of 2mg/day for 5 consecutive days. Both Cre+ and Cre- mice were treated with tamoxifen.
In all cases, Cre+ mice were hemizygous for Cre.
Immunohistochemistry: Mice were deeply anesthetized with pentobarbital, followed by
transcardiac perfusion with cold PBS + 5% heparin for 3 minutes. Brain were then removed and
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drop-fixed in 3% paraformaldehyde for 24 hours at 4°C, then incubated with 30% sucrose
solution for at least 48 hours at 4°C. Fixed, frozen brains were sectioned on a Leica sliding
microtome to generate 40 micron coronal sections, which were stored at -20C in cryoprotectant
solution containing 30% ethylene glycol, 15% sucrose, 15% phosphate buffer in ddH20. Sections
were mounted on slides and coverslipped with Prolong Gold mounting reagent. The following
antibodies were used: TH (Millipore Sigma, AB152, 1:2000), BMAL1 (Novus, NB100-2288,
1:2000), Iba1 (Abcam, AB5076, 1:500), NeuN (Millipore Sigma, MAB377, 1:2000), P-syn
(BioLegend, 825704, 1:1000). Sections were washed three times for five minutes each in trisbuffered saline (TBS), then blocked and permeabilized in TBS containing 0.25% Triton X-100
(TBSX) containing on 3% goat or donkey serum (Abcam) at room temperature with shaking,
followed by overnight incubation with primary antibody diluted in TBSX containing 1% goat or
donkey serum at 4°C overnight with shaking. The sections were then washed three times for 5
minutes each in TBSX, followed by incubation with secondary antibodies for two hours at room
temperature with shaking. For immunofluorescent microscopy, sections were incubated with
fluorescently-labeled secondary antibodies at 1:1000 dilution in TBSX with protection from
light, then washed in TBSX and mounted. For DAB-stained sections, a biotinylated secondary
antibody (Vector, BA-1000) was used at 1:1000, and sections were then washed three times in
TBSX. The tissue was then incubated with HRP-streptavidin (Vectorshield) for two hours in
TBS at room temperature with shaking. Sections were then washed again with TBS for 3x5
minutes with shaking, then incubated with diaminobenzidine solution with 0.25% of 4% nickel
chloride and 0.05% of 30% hydrogen peroxide for 2-5 minutes. The tissue was then mounted and
left out to dry for 24 hours. The mount tissue was then washed in water twice for two minutes,
then incubated in cresyl violet solution (0.25g cresyl violet in 250mL MQH2O, add ~20 drops
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glacial acetic acid and filter) for two minutes. Tissue was then serially dehydrated in 50%, 70%,
90%, 95%, and 100% ethanol for one minute each. Following the ethanol washes, the tissue was
then placed in two washes of xylene for four minutes each and then coverslipped.
Immunoreactivity quantification: Epifluorescent and bright field images were taken with the
Keyence BZ-X810 microscope (Keyence, Osaka, Japan) at 10x. Images were then quantified
using ImageJ software (NIH). The images were then thresholded by hand to encompass all
immunoreactivity, and a threshold value was set and maintained for all sections. Percent area
coverage was then calculated for each image. In general, 1 image from each section and 2
sections/mouse were averaged, and the average from each mouse used as a data point.
Particle count: Fluorescent images were taken with the Keyence BZ-X810 microscope at 10x.
The images were then analyzed using ImageJ software (NIH). Regions of interest were drawn
around the SNpc so as to only quantify the TH+ particles in this region. The images were then
subjected to a color correction, and then thresholded by hand. The thresholded images were then
analyzed using the “analyze particles” command. The size (pixel^2) function was then corrected
to include particles from 10-800 pixels^2. The default circularity of 0-1 was not changed. The
images were then converted to outlines, and the output value titled as “counts” were recorded as
the number of particles in the image. Four SNpc sections from each mouse were included for the
analysis, and the average of the four values were used to determine the amount of TH+ particles
for a given mouse.
Stereology: Stereologic cell counting of TH+ cells in the SNpc was performed on a Nikon
Eclipse E800 microscope, using StereoInvestigator software (Microbrightfield Inc., Williston,
VT, USA) to obtain unbiased optical fractionator estimates of the total number of TH+ cells
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within the SNpc. These assessments were gathered using the methods described (Bukhatwa et
al.). Briefly, sections were obtained by randomly choosing the first section, followed by every
fifth section thereafter. Gunderson coeffeicents were calculated, and kept at or below 0.1 (m=0)
and 0.06 (m=1). One hemisphere was analyzed per mouse and all assessments were performed in
a blinded manner.
Skeletonization: Images of Iba+ cells were acquired from the SNpc using a Zeiss LSM 800
confocal microscope. Morphological analysis of confocal images was acquired using the protein
marker Iba1. Images were taken at 20x and were analyzed using ImageJ software (NIH). The
images were modified as 8-bit and Z-stack projection images, then the resulting images were
smooth processed, binarized, and skeletonized, using the Skeletonize Plugin. A mask of the
images was then created using the particle analysis function to subtract from skeletonized
images. The resulting images were processed using the Analyze Skeleton 2D 3D option in the
Skeletonize Plugin, and the number of branches per cell were obtained from the Results tables.
Three sections from each mouse were used for this experiment, and 1-2 images from each
section were taken. Three Iba1+ microglia were randomly chosen from each image, resulting in
10 analyzed microglia for each mouse. The average of all ten microglial branching outputs was
used as a data point for each mouse.
Alpha-synuclein fibril preparation and stereotactic injection: Purification of recombinant mouse
sequence Syn monomer and in vitro fibril assembly were performed as described with minor
modifications (Davis et al., 2020; Volpicelli-Daley et al., 2014). Briefly, fibril assembly
reactions were carried out in an Eppendorf ThermoMixer at 1000 rpm for 3 days. An aliquot of
the resulting suspension was centrifuged at 15,000g for 20 min, and the PFF concentration was
estimated by subtracting the concentration of Syn monomer in the resulting supernatant from
91

the starting monomer concentration. PFFs were aliquoted and stored at −80°C until use. Before
use, aliquots were thawed and sonicated briefly in a water bath sonicator. Mice at approximately
3 months old were anesthetized with isoflurane and stereotactically injected with 2.5 l of Syn
PFF suspension (about 4 g) into the left dorsal striatum (0.5 mm anterior and 2.2 mm lateral to
bregma and 3.2 mm below the surface of the skull) using a Hamilton microsyringe attached to a
motorized injector (Stoelting, Wood Dale, IL). At 3 months after injection, animals were
anesthetized with pentobarbital followed by perfusion for two minutes with PBS. Whole brains
were removed and fixed in 4% paraformaldehyde for 48 hours, then transferred to a 30% sucrose
solution for another 48 ours before sectioning. 40 micron coronal sections were taken from
whole brain and stored in cryoprotectant for later use.
Transcriptomic analysis: Total mRNA was isolated from frozen cerebal cortex samples as
previously described. Briefly, tissue was submerged in Trizol reagent (Invitrogen/ThermoFisher)
and mechanically dissociated using a bead homogenizer. Chloroform extraction was performed,
and the supernatant was collected and mRNA was isolated using Ambion PureLink RNA
iolation kit (ThermoFisher), following the manufacturers instructions. RNA sequencing and
analysis were performed by the Genome Technology Access Center at Washington University
using their standard methods, which are summarized here: Sample RNA integrity was
determined using a Tapestation and library preparation was performed with 10ng of total RNA
for samples with a Bioanalyzer RIN score greater than 8.0. ds-cDNA was prepared using the
SMARTer Ultra Low RNA kit for Illumina Sequencing (Takara-Clontech) per manufacturer's
protocol. cDNA was then fragmented using a Covaris E220 sonicator using peak incident power
18, duty factor 20%, cycles per burst 50 for 120 seconds. The cDNA was blunt ended, had an A
base added to the 3' ends, and then had Illumina sequencing adapters ligated to the ends. Ligated
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fragments were then amplified for 12-15 cycles using primers incorporating unique dual index
tags. The fragments for each sample were then pooled in an equimolar ratio and sequenced on an
Illumina NovaSeq-6000 using 150 base pair paired end reads. Basecalls and demultiplexing was
performed with Illumina’s RTA 1.9 software and the reads were aligned to the Mus musculus
Ensembl release 76 GRCm38 primary assembly with STAR version 2.5.1a. Gene counts were
quantitated with Subread:featureCount version 1.4.6-p5.
All gene counts were then imported into the R/Bioconductor package EdgeR and TMM
normalization size factors were calculated to adjust the samples for differences in library size.
Ribosomal genes were removed and only genes expressed greater than one count-per-million in
at least four samples were kept for further analysis. The adjusted TMM size factors and the
matrix of counts were then imported into the R/Bioconductor package Limma. Weighted
likelihoods were then calculated for all samples and the count matrix was transformed to
moderated log 2 counts-per-million with Limma’s voomWithQualityWeights.
Differential gene expression was calculated using R package DESeq2. Volcano plot was
constructed using the package EnhancedVolcano with fold change cutoff of 1.5 and pvalue
cutoff of 0.05. KEGG pathway gene set enrichment analysis was performed using R package
clusterProfiler and enrichplot.
Statistics: Data was analyzed using GraphPad Prizm 9.1.0. 2-tailed Student’s T-test was
performed on datasets with 1 variable and Gaussian distribution. For 2-variable datasets, 2-way
ANOVA with Tukey’s multiple comparisons test was used.

93

Chapter 4: Glia Reprogram Rhythmic Gene
Translation during aging and disease
4.1 Abstract
As described earlier, nearly every cell in the human body has a circadian clock which
mediates a myriad of rhythmic cellular functions. These circadian processes are controlled by
circadian rhythms in gene transcription, which has been demonstrated in many organs and brain
regions. Data from peripheral organs show that the circadian transcriptome is highly cell type
dependent and varies dramatically from tissue to tissue, presumably to subserve different tissuespecific demands. Moreover, sets of transcripts can gain or lose circadian rhythms in a contextdependent manner, a poorly-understood phenomenon known as circadian reprogramming. This
circadian reprogramming is also tissue-specific and can play important roles in stress responses
in the setting of disease. Considerable data shows that astrocytes and microglia display robust
circadian rhythms in numerous processes, but the genes driving these events are unknown.
Given that these cells are the primary immune cells of the brain and play critical roles in
mediating neurodegenerative diseases, we sought to define the circadian transcriptomes of
astrocytes and microglia in vivo in in healthy mouse brain, aging, and a neurodegenerative
disease model. To do so, we used a modified version of the Translating Ribosome Affinity
Purification (TRAP) and Ribotag method in which we harvested mouse cortex tissue at 2-hour
intervals across the circadian cycle under constant lighting conditions, then isolated cell typespecific, ribosome-associated mRNA and performed bulk RNAseq. We used mice with
astrocyte- (Aldh1l1-TRAP) and microglia-specific (Cx3cr1-Cre-RiboTag) ribosomal tags that
were either young adults (5mo), aged (22 months), or had Alzheimer’s Disease (AD) –associated
amyloid plaque pathology (APP/PS1-21 mice, 5mo). We found that we could obtain 10-20 fold
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enrichment of astrocyte or microglia-specific RNA, and used a robust bioinformatics algorithm
(JTK_Cycle) to identify rhythmic transcripts. Interestingly, we identified approximately 400
genes in astrocytes and over 1000 genes in microglia which met statistical criteria for circadian
expression expressed in healthy mouse cortex. Aside from core circadian clock genes, there was
little overlap in the circadian translatomes of astrocytes and microglia, suggesting cellular
specificity of the clock. There was also massive reprogramming of both astrocyte and microglial
circadian translatomes in response to either amyloid pathology or aging, with several hundred
genes gaining or losing circadian regulation in each condition. Oscillating genes were almost
entirely specific to each condition, with very little overlap. Surprisingly, in astrocytes and
microglia exposed to amyloid pathology, several critical AD risk genes gained rhythmic
expression, suggesting that some disease-related responses of these cells may be regulated by the
circadian clock. Furthermore, aged microglia and astrocytes gained rhythmic expression of
genes involved in stress-related pathways including the unfolded protein response and
autophagy. Our data are the first to define the circadian translatomes of glia in vivo in health,
aging, and disease, and to demonstrate that astrocytes and microglia undergo dramatic circadian
reprogramming in gene expression that is highly context-dependent. Our findings reveal glia
circadian clocks as critical regulators of specific transcriptional responses to aging and disease,
and have broad implications for the study of glial responses in neurodegenerative diseases.

4.2 Introduction
The molecular circadian clock consists of a number of transcription factors that make up
a transcription-translation feedback loop that is synchronized to daily light cycles. These
oscillatory transcription factors give rise to circadian rhythms in cell-specific
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functions(Takahashi, 2017). This has been especially evident in the peripheral immune system
as many leukocytes are rhythmically recruited to various tissues across the circadian cycle
(Druzd et al., 2017). These rhythms persist in disease states like cancer where recent evidence
suggests that breast cancer cells spread mostly at night(Diamantopoulou et al., 2022). Cellspecific rhythmic gene transcription underlies these various circadian rhythms in cell function.
Circadian transcription factors, like Bmal1, can directly regulate rhythmic expression of genes,
or can exert its rhythmic properties onto other transcription factors, which then creates rhythms
in gene expression downstream(Altman et al., 2015). This process was once thought to be
stagnant across life and different disease states, but recent paradigm-shifting work in the
circadian field suggests that genes can gain or lose rhythmic transcription over the course of
normal aging, or when the cell encounters new conditions (Eckel-Mahan et al., 2013b; Solanas,
Peixoto, Perdiguero, Sassone-corsi, & Benitah, 2017; Tognini et al., 2017). This phenomenon,
termed circadian reprogramming, can dramatically impact efficacy of drug delivery if the gene
being targeted gains rhythmic expression in a disease state as has been shown with
hyperlipidemia (Guan et al., 2018). This suggests that gaining an understanding of how various
cell types reprogram circadian gene transcription could be very important for understanding cell
function and treating disease.
Very little is known about the rhythmic functions of microglia and astrocytes. Even less
is known about genes that can be rhythmically expressed by either cell type. Furthermore, it has
yet to be shown if astrocytes or microglia can reprogram their rhythmic gene transcription in the
setting disease. Given that GWAS studies largely point to glia as initiators of disease, and since
a huge amount of work is being done to target specific genes in astrocytes and microglia to
reduce AD pathogenesis, it goes to reason that understanding genes that are being rhythmically
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expressed in these cell types could dramatically influence our timing of drug delivery(Novikova
et al., 2021; Qiao et al., 2021). In this study, we identify genes that are being rhythmically
expressed in cortical astrocytes and microglia in WT mice. To understand if astrocytes and
microglia are undergoing circadian reprogramming in vivo in the presence of AD pathology, we
once again identify the rhythmic genes being expressed in astrocytes and microglia in a mouse
model developing amyloid beta plaques. Here we find that astrocytes and microglia dramatically
reprogram rhythmic gene transcription in disease where a large number of AD-associated genes
gain or lose rhythmic expression in each cell type. Finally, we asked if aging induced similar
gene sets in each cell type to gain rhythmic expression as they do around plaques. To our
surprise, genes that gain rhythms during aging in both astrocytes and microglia were highly
divergent from the genes that gained rhythmic expression in the presence of amyloid plaques.
Our findings are the first to suggest that microglia and astrocytes undergo circadian
reprogramming during aging and disease, which could hold tremendous consequences for the
future of treating neurodegenerative diseases.

4.3 Results
4.3.1 Single Nuclei Sequencing cannot resolve circadian gene expression.

Initially, to try to identify circadian reprogramming in various cell types, we decided to
use single nuclei sequencing. WT mice were sacrificed at 7am and 7pm, two time points where
we know circadian transcription factors in every cell type peak and trough. Thus, we should
have a good positive control to threshold the rhythms that we are seeing in every cell type.
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Figure 4.1. Resolution of circadian gene using single nuclei sequencing. (A) UMAP plots of
cortical brain samples split into 24 cell types between 7am and 7pm. Two mice pooled per
sample. (B) Analysis of the astrocyte cluster shows high expression of astrocyte marker gene,
Slc1a3, but no expression of circadian genes. (C) Differential gene expression of astrocytes
between 7am and 7pm does not show any circadian genes.

UMAP plots were created using Seurat at each time point revealing no differences in number of
cell clusters per time point (Fig. 4.1A). Using the astrocyte cluster as a proof of concept, we
specifically looked for a few of the circadian transcription factors that should be peaking and
falling at 7AM/7PM. Unfortunately, while we were able to identify high expression of astrocyte
specific marker, Slc1a3, we did not observe any expression of circadian transcription factors
(Fig. 4.1B). To see if there were other genes that could be oscillating with higher amplitude in
our datasets, we took the astrocyte cluster and compared gene expression of all genes between
7AM and 7PM and saw no promising genes. Thus, our attempt at single cell sequencing could
not resolve circadian transcription factors or oscillations in expression of other cell types. In the
future, detecting rhythms in single cell sequencing could be made possible by increasing the read
depth by a very large amount.

4.3.2 TRAP and Ribotag efficiently enrich for astrocyte and microglia RNA
across time and is consistent between batches

As a second approach to identifying circadian reprogramming in glia, we then turned to
Translating Ribosome Affinity Profiling (TRAP) and Ribotag methods as an in vivo approach to
assay rhythmic gene expression. These methods stood out to us over cellular isolation protocols
99

because many studies have reported artifacts when isolating glia that are not replicated in vivo
and activation of certain genes would make it difficult to detect oscillations in expression. Both
TRAP and Ribotag are based on the same general concept where a cell specific promoter
(Aldh1l1 for astrocytes and Cx3cr1 for microglia) drive expression of a tag on ribosomes. When
the mouse is sacrificed, they are perfused with a cycloheximide solution that stops ribosomes in
place. After isolating the cortex, it can be frozen and cell-specific ribosomes with their attached
RNAs can be pulled down later (Fig 4.2A). To assay circadian reprogramming we thus used
TRAP and Ribotag mice that had been crossed to a mouse line that develops amyloid plaques
over time, referred to from here on out as APP. Both WT and APP mice were aged to six
months old and then sacrificed every two hours over a 24 hour period. To also assess if
circadian reprogramming occurs in another model of inflammation, we also aged TRAP and
Ribotag mice to 22 months old, when there is a large amount of neuroinflammation and
sacrificed these mice every four hours over a 24 hour period (Fig 4.2B). To understand if our
methods are efficiently enriching for their respective cell types, we picked out multiple cell
markers and looked at their general expression level prior to immunoprecipitation of cell-specific
ribosomes (referred to a Bulk) (Fig 4.3A). Here, we saw no enrichment in any one cell type.
However, when looking at the TRAP samples, we found that we enrich for astrocyte transcripts
5-15 fold and with the Ribotag samples, we enrich for microglia transcripts 10-20 fold. We also
used circadian transcription factors that are known to oscillate in every cell type to compare
expression levels between the two batches of sequencing that we ran and found that even
samples collected and sequenced months apart showed consistent oscillations at a very similar
phase.
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Figure 4.2. The TRAP and Ribotag methodology and mice used to generate rhythmic
datasets. (A) A schematic of the TRAP method used to isolate in vivo astrocyte RNA at 2 hour
time points. The ribotag method is the same except for a microglia-specific promoter (Cx3cr1)
driving an HA tag on microglia ribosomes. (B) All TRAP and Ribotag mice used to generate
rhythmic datasets.
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Figure 4.3. TRAP and Ribotag efficiently enrich for astrocyte and microglia RNA and is
consistent between batches sequenced. (A) Bulk sequencing on cortex does not show
enrichment of any cell-specific transcripts. (B) The TRAP method enriches for astrocyte
transcripts by about 5-15 fold. (C) Ribotag enriches for microglia-specific transcripts 10-20
fold. N = 24 samples per group. (D) CPM values of various known circadian genes across the
two sequencing batches. Each dot represents one mouse. Data are double-plotted, with dotted
line showing repeated data.
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Figure 4.4. Circadian reprogramming exists in astrocytes. (A) Genes specifically identified to
be rhythmic in WT Astrocytes (left). The same genes are plotted in APP astrocytes (right). (B)
Genes specifically rhythmic in APP astrocytes (left) with the same genes plotted in WT
astrocytes (right).
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Figure 4.5. Comparing all rhythmic genes in astrocytes and microglia shows dramatic
reprogramming between datasets. (A) All rhythmic genes identified in each of the three
astrocyte and (B) microglia datasets.

4.3.3 Astrocytes and microglia undergo dramatic circadian reprogramming
during aging and disease
To understand if astrocytes undergo circadian reprogramming in the context of amyloid
plaques, we analyzed out RNAseq data from isolated astrocyte samples taken every two hours
usingJTK cycle, a software developed for identifying rhythms in gene expression in large
sequencing datasets. Here, I identified a number of genes that were being rhythmically
expressed in WT astrocytes and plotted them in a heatmap, ordering the genes by the timing of
peak expression (phase). To understand if these same genes are oscillating in astrocytes around
plaques, we took the same genes and plotted them in the APP astrocytes and saw that many of
these genes lost rhythms in expression (Fig. 4.4A). To understand if any genes gained rhythmic
expression in astrocytes
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Figure 4.6. Specific pathways gain or lose rhythmicity in WT, APP, and Aged astrocytes.
(A) GO pathways specifically rhythmic in WT astrocytes with Cdkn1a as an example gene in the
“Regulation of Double-strand Break Repair” pathway. (B) GO pathways specifically rhythmic in
APP astrocyte with Ccl3 as an example gene in the “Response to TNF pathway.” (C) GO
pathways specifically rhythmic in Aged astrocytes with mTOR as an example gene in the
“Autophagy” pathway.

around amyloid plaques, we ran JTK cycle on the APP astrocytes and found a number of genes
specifically oscillating in expression in these astrocytes that were normally non-rhythmic in WT
astrocytes (Fig. 4.4B). Upon analysis of the microglia data, we found the same exact trend. This
suggests that circadian reprogramming is, in fact, happening in astrocytes and microglia in the
presence of amyloid plaques. To better visualize the overlap in rhythmic genes between datasets,
we created a Venn diagram with all astrocyte and microglia datasets and found that there was
dramatic circadian reprogramming in both the setting of plaques, and during normal aging. This
suggests that the genes that are being rhythmically expressed in astrocytes and microglia are very
sensitive to the extracellular context such that when they face a new context, they reprogram the
majority of their rhythmically-expressed genes.
To better understand what rhythmic functions astrocytes are performing in each
condition, we performed GO analysis on the genes that were rhythmically expressed specifically
in each condition. Interestingly, we found that WT, APP, and Aged astrocytes perform very
unique functions in a circadian manner. In WT astrocytes, amyloid beta metabolism and
receptor mediated endocytosis were both rhythmic with a number of genes in each category only
rhythmic in WT astrocytes (Fig. 4.6A). APP astrocytes gained rhythms in a number of
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inflammatory pathway like TLR4 pathway, response to TNF and apoptosis. One interesting
gene to gain a rhythm in APP astrocytes that is also part of the response to TNF pathway is Ccl3,
which is normally not expressed in WT astrocytes, but as soon as it is, it gains a high-amplitude
rhythm in expression (Fig. 4.6B). A number of interesting pathways gained rhythmic regulation
in aged astrocytes including autophagy, regulation of catabolism, and autophagosome assembly.
A very interesting gene to gain rhythmic expression in aged astrocytes within these pathways in
mTOR (Fig 4.6C). These data demonstrate that, not only do individual genes gain/lose rhythms
in astrocytes in different settings, but whole pathways can gain/lose rhythms in expression based
on the extracellular environment of the cell.
We next wanted to ask if any of these rhythmic genes were important in the progression
of Alzheimer’s disease pathology. Clusterin (Clu) was one of top hits for rhythmic genes in our
APP astrocyte dataset, where it gains rhythmic expression in the setting of amyloid plaques.
Interestingly, Clusterin is an Alzheimer’s Disease GWAS risk factor and has been shown to
significantly affect the progression of disease(Wojtas, Carlomagno, et al., 2020; Wojtas, Sens, et
al., 2020). To understand how the time of day could impact differential gene expression analysis
of Clusterin when comparing between WT and APP astrocytes, we binned expression between
early morning and afternoon. Remarkably, when we look at expression of Clusterin early in the
morning between WT and APP astrocytes, we see no difference in expression, but when we look
in the afternoon, we see a large difference due to the new rhythm in expression. This suggests
that the time of day when mice are sacrificed to look at Clusterin expression, as well as many
other oscillatory genes, may significant impact differential gene expression analysis. To
understand if any other AD GWAS risk factors were rhythmically expressed in any of our
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rhythmic datasets, we scanned the total list of the 48 AD risk factors and identified the rhythmic
genes in each of our datasets. In total, 19 of 48 risk factor genes were

A.

C.

B.

Figure 4.7. Many AD risk genes are rhythmic in at least one glia dataset. (A) AD GWAS
risk gene, Clusterin (Clu) gains rhythmic expression in APP astrocytes. (B) Binning WT and
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APP astrocytes into early morning an afternoon to look at differential gene expression. (C) A list
of all AD GWAS hits that are also rhythmic in at least one dataset.

rhythmically expressed in at least one dataset. Interestingly, the majority of risk factors
transcripts oscillated in WT microglia and lost rhythmic expression in the setting of plaques and
normal aging. This could suggest that the loss of rhythms in some of these risk factors could
have negative effects on disease outcomes as we age.

4.3.4 Astrocytes lose coordinates gene expression around amyloid plaque
pathology
We next asked what time of day genes were peaking in expression in each of the
astrocyte datasets. To visualize the percent of genes peaking at each time point, we created radar
plots for WT, APP and Aged astrocytes. Doing this, we can see that the time genes peak in WT
astrocytes is largely biphasic, whereas aged astrocytes largely only peak at one time of day. APP
astrocytes, on the other hand, do not seem to have a coordinated time when they peak in
expression. To visualize this another way, we built a histogram where we could visualize the
number of peaks in expression over the course of the day. Once again we can see that APP
astrocytes don’t have a coordinated time when certain genes peak in expression. We then asked
if there were motifs present in the promoter region of rhythmically expressed genes in astrocytes
in each condition and found that the majority of rhythmic genes in WT astrocytes had a motif in
the promoter for RARG, while no significant enrichment was identified in Aged astrocytes,
though NFIA was the strongest non-sifnificant hit. No specific motifs were enriched in rhythmic
genes in APP astrocytes, again suggesting that there is some loss of coordination in rhythmically
expressed genes around amyloid plaques.
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Figure 4.8. Astrocytes lose coordinated gene expression around amyloid plaques. (A) Radar
plots of WT, APP and Aged astrocytes. (B) Histogram of the timing of peak expression of
oscillating transcripts. (C) Enriched motifs present in WT. APP, and Aged astrocyte rhythmic
genes.

4.4 Discussion
Here we describe circadian reprogramming in astrocytes and microglia in vivo in the
setting of amyloid plaques and normal aging. We were able to define genes that are being
rhythmically expressed in WT astrocytes and microglia and surprisingly found that the majority
of these genes lost rhythms in expression but a whole new set of genes gained rhythms around
plaques or during aging. We also show that single nuclei sequencing is not a good method for
interrogating gene oscillations while TRAP and Ribotag are consistent between batches, and
sufficiently enriches for in vivo cell-specific RNA. Finally, we show that a large number of
Alzheimer’s Disease risk factors oscillate in at least one of datasets, suggesting that these
oscillations in gene expression may be important for normal physiology.
A persistent question in the field of medicine is at what time to dose people for maximum
effectiveness. Many drugs are already prescribed for a certain time of day because of known
circadian effects. For example, cholesterol and blood pressure oscillate over the course of the
day and both medications are most effective at night due to their inherent rhythmicity. It has
recently been suggested that timing of chemotherapy results in differences in effectiveness,
possibly due to findings from a new report where cancer cell mostly metastasized at night. A
paper from Mitch Lazar’s group a few years ago found that high fat diet induced circadian
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reprogramming in the liver such that PPARα gained a large amplitude rhythm. Since PPARα
agonists are used in the clinic to treat hyperlipidemia, they tested whether this new rhythm
resulted in altered effectiveness of the drug at different times of day. Sure enough, giving the
PPARα agonist at the new peak of expression was much more effective in clearing lipid deposits
from the liver. This demonstrates that genes can gain rhythms due to circadian reprogramming,
which can have downstream consequences for drug delivery.
Future studies will no doubt demonstrate circadian reprogramming in human patients. At
this point, there are hundreds of people that have been sequenced with, and without pathology.
To understand circadian reprogramming at the bulk level in these people, we should be able to
align autopsy reports with the time of death such that their sequencing results can be matched to
a specific time point. This may be able to affirm some of our mouse findings that circadian
reprogramming exists in humans, and that AD GWAS hits oscillate and lose rhythmic expression
during aging and disease. Other experiments should focus on the mechanism of how circadian
reprogramming is occurring, as that is not understood in the field. Using methods like CHIP-seq,
we should be able to tell if circadian transcription factors like BMAL1 are binding to different
promoter regions after reprogramming has occurred. Another approach would be to use ATACseq to see if rhythms in chromatin opening change in the setting of circadian reprogramming.
Other methods, like TurboID would be beneficial for seeing if BMAL1 physically interacts with
a different set of transcription factors in disease states. Some evidence suggests that BMAL1
physically tethers itself to other transcription factors, making them rhythmic(Altman et al.,
2015). To see if BMAL1 is physically interacting with a different set of transcription factors
after circadian reprogramming, TurboID can be used on BMAL1 to biotinylate all the proteins it
comes into contact with. Quantification with Mass Spectrometry should help us understand how
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circadian transcription factors could make large sets of genes gain and lose rhythms in different
contexts.
In summary, we’ve shown that astrocytes and microglia dramatically reprogram their
circadian gene transcription during aging and disease and that this reprogramming may hold
relevance for treating AD. We hope these rhythmic datasets of astrocytes and microglia in
different disease contexts will be helpful to the broader scientific community as a way to help
plan timing of experiments and dosing regimens when investigating new drugs.

4.5 Materials and Methods
Mice: All animal experiments were approved by the Washington University IACUC and were
conducted in accordance with AALAC guidelines and under the supervision of the Washington
University Department of Comparative Medicine. Aldh1l1-RPL10eGFP(TRAP) mice were given
to us from Joseph Dougherty’s lab at Washington University in St. Louis. Cx3cr1CreErt2-IRESeYFP/+

, RPL22HA/+ (Ribotag) mice were given to us from John Fryer’s group. Both TRAP and

Ribotag mice were crossed with APP/PS1 mice in-house. Ribotag mice were treated with 150ul
of 2mg/mL tamoxifen for 5 days. Ribotag mice were sacrificed approximately four weeks after
tamoxifen treatment. For circadian time points, mice were single housed and kept in a dark room
for at least 24 hours before they were sacrificed. At the time of sacrifice, mice were injected
with Fatal plus before being perfused with a 100ug/mL solution of cycloheximide+PBS. After
two minutes of perfusion, the cortex was dissected and placed into a tube on dry ice. The TRAP
and Ribotag methods for pulling down cell-specific RNA were performed as previously
described.
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Transcriptomic analysis: Total mRNA was isolated from frozen cerebral cortex samples as
previously described. RNA sequencing and analysis were performed by the Genome
Technology Access Center at Washington University using their standard methods, which are
summarized here: Sample RNA integrity was determined using a Tapestation and library
preparation was performed with 10ng of total RNA for samples with a Bioanalyzer RIN score
greater than 8.0. ds-cDNA was prepared using the SMARTer Ultra Low RNA kit for Illumina
Sequencing (Takara-Clontech) per manufacturer's protocol. cDNA was then fragmented using a
Covaris E220 sonicator using peak incident power 18, duty factor 20%, cycles per burst 50 for
120 seconds. The cDNA was blunt ended, had an A base added to the 3' ends, and then had
Illumina sequencing adapters ligated to the ends. Ligated fragments were then amplified for 1215 cycles using primers incorporating unique dual index tags. The fragments for each sample
were then pooled in an equimolar ratio and sequenced on an Illumina NovaSeq-6000 using 150
base pair paired end reads. Basecalls and demultiplexing was performed with Illumina’s RTA
1.9 software and the reads were aligned to the Mus musculus Ensembl release 76 GRCm38
primary assembly with STAR version 2.5.1a. Gene counts were quantitated with
Subread:featureCount version 1.4.6-p5. To detect rhythms in datasets, JTK analysis was used in
the metacycle R package.

Chapter 5: Future Directions
The circadian clock plays a significant role in many facets of biology, especially in terms
of neurodegeneration and Alzheimer’s disease (AD). In this thesis, we address how the circadian
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clock and AD can have a bidirectional relationship through multiple projects. Here, we will
describe the main findings from each one of those projects and discuss future directions where
each project could be expanded in order to understand fundamental and potentially important
aspects of biology.
In the first project, we show that astrocytic deletion of Bmal1 induces an activation state
that is capable of reducing intra-neuronal proteins aggregates. We further show that this
activation profile may also be present in human astrocytes, but turned on too late to be beneficial.
While our data suggests that upregulation of Bag3 is necessary to drive this phenotype, there are
likely other proteins that come into play. Therefore, we want to ask what genes in astrocytes are
needed to fully recapitulate the phenotypes that we observe. One way to address this would be to
look at gene expression profiles in other astrocytes manipulations that are also able to reduce
intra-neuronal protein aggregates. Work recently has shown that constitutive activation of Jak2
in astrocytes is able to reduce Huntington pathology, another intra-neuronal protein aggregate
(Maté De Gérando et al., 2021). Therefore, if we compare the transcriptional profiles of Bmal1KO astrocytes and constitutively active Jak2 astrocytes, by looking at genes that are similarly
dysregulated in both datasets, we should be able to narrow down genes of interest. Once we
narrow down the list of genes that could be playing a role in degradation of intra-neuronal
proteins, we can use the PFF-phrodo in vitro assay that we developed in order to assay each gene
using siRNAs or a CRISPR-based strategy. By doing this, we can hopefully define astrocytic
genes that would be beneficial to target to reduce intra-neuronal protein aggregates. Another
important question to consider here is how astrocytes are able to “catch” protein aggregates as
they are being passed trans-synaptically between neurons. Our hypothesis here is that endfeet
from activated astrocytes at the tripartite synapse are better able to take up and degrade proteins
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being passed in the synapse. One way to assess this is by tagging all proteins that are made by a
specific cell type using a new TurboID mouse model that labels all endogenously made
proteins(Rayaprolu et al., 2022). We can then induce trans-synaptic protein spreading using our
synuclein fibril injection model and then isolate astrocyte endfeet for mass spectrometry
analysis. Since all endogenous protein will be labeled, we should be able to see non-astrocytic
proteins in the astrocyte endfeet and thus we should be able to see if intra-neuronal synuclein
aggregates are detected in those astrocyte endfeet. If they are, that suggests that astrocytes can,
in fact, take up protein aggregates that are being passed trans-synaptically. We can then
manipulate astrocyte endeet to see if increasing astrocyte endfeet coverage at the synapse would
be beneficial for reducing the passage of protein aggregates between neurons. To do this, we can
knockdown connexin 30 to increase astrocyte branching morphology(Pannasch, Dossi, Ezan, &
Rouach, 2019). Since knockdown of connexin proteins can have many off-target effects, we can
also knockdown neuroligin 2 in order to reduce the number of astrocyte branches(Stogsdill et al.,
2017). Here, we would expect that decreasing astrocyte branches using neuroligin 2 knockdown
would increase the rate at which neurons pass protein aggregates trans-synaptically. In this
project, we have highlighted the role astrocytes can play in reducing intra-neuronal protein
aggregates and hope that further research will lead to more astrocyte manipulations that can
prevent the spreading of disease pathology.
In the second project, we show that Bmal1 controls dopaminergic cell death in a cellautonomous manner. These findings suggest that keeping an intact clock in these neurons may
be beneficial for preventing their degeneration. Our leading hypothesis for how these cells are
degenerating, is that loss of Bmal1 results in increased cell-specific oxidative stress. Since we
know that dopaminergic neurons are very susceptible to oxidative stress, they are the most likely
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population of neuron to die after Bmal1 deletion. To truly show this, we can first treat mice with
Bmal1 deletion with N-Acetyl Cysteine (NAC). Since NAC is an antioxidant, if dopaminergic
cells are dying after Bmal1 deletion due to oxidative stress, treatment with NAC should rescue
that effect. It would also be worth creating an intro model to investigate more mechanisms of
how Bmal1 could be causing cell death. Since primary dopaminergic neurons are very difficult
to make, we could use IPSC-derived dopaminergic neurons. This way, the majority of cells in
the well are dopaminergic neurons, and we could treat them with viruses to knockdown Bmal1.
Doing this, we can sequence these cells as they die to ask what genes are being upregulated after
Bmal1 knockdown to cause this dopaminergic neuron cell death. Recently, a new report came
out describing multiple populations of dopaminergic neurons in the substantia nigra of patients
with and without Parkinsons’s Disease (PD) using single cell sequencing. They leveraged their
large single cell sequencing database of patients in order to describe a single population of
dopaminergic neurons that degenerates in PD. It would be interesting to really dig into this data
and see the transcriptional profile of those neurons that selectively degenerate. We could then
query this dataset to ask if these degenerating neurons have any irregularities in the expression of
circadian genes, like Bmal1. If this population of dopaminergic neurons expresses less Bmal1
than others, that might make them more susceptible to cell death via oxidative stress.
Finally, in the third project we define the genes that are being rhythmically expressed by
cortical astrocytes and microglia. We also find that the rhythmic gene expression profile of each
of these cell types changes during disease and aging, a process known as circadian
reprogramming. It is incredibly interesting that the shift in rhythmically expressed genes
between conditions is so dramatic, but it begs the question of how many genes can be put on a
circadian cycle? Could every gene be rhythmic in at least one context? To answer this, it would
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be interesting to define the rhythmic expression profile of astrocytes in other models, such as
mouse models of tauopathy. Are there genes that gain rhythmic expression in amyloid plaques
models that also gain rhythms in tau models? How are these rhythmic profiles similar?
Furthermore, one of the most important questions in the field is how exactly these genes are
being reprogrammed at a genomic level. This is a question that is being asked across that
circadian field but is hard to address without an in vitro model to explore cell-specific
reprogramming. To do this, we have to first make the assumption that in old age, many cells
become senescent. We can then take primary astrocyte in vitro and treat them with hydrogen
peroxide for a short amount of time to induce senescence. We can then synchronize these cells
and sequence them every four hours to see if we see a similar reprogramming phenotype in vitro.
If we do, we can start asking question about how and why this mechanism is occurring in cells.
One theory I have as to why circadian reprogramming is happening is to target genes that are
being expressed constitutively, and put them under circadian control in order to reduce physical
demand from the cell. To test this, we can use our aged in vitro reprogramming paradigm and
assay a few genes every day after treating with hydrogen peroxide. Doing this, we should be
able to observe the amplitude increasing of genes that are becoming reprogrammed. Therefore,
we can see how long it takes for a cell to reprogram to its maximum extent. We can then check
metabolic indicators like glucose utilization as reprogramming occurs. I hypothesize that the
immediate insult of hydrogen peroxide will cause glucose utilization to peak, which will slowly
fall back to baseline as genes are reprogrammed. How circadian reprogramming happens is
another open question in the field. We could also use our aged in vitro model here and do CHIPseq experiments to see if Bmal1 is binding to a different set of transcription factor during aging
that causes rhythmicity of their downstream transcripts. Another way of going about this would
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be to do TurboID to see what Bmal1 is physically interacting with in our aged in vitro model (or
possibly in vivo).
Through these projects described in this thesis, I hope to have contributed to our
understanding of circadian rhythms and how they impact neurodegenerative disease pathology,
and conversely how pathology can impact circadian rhythms. It is our hope that these projects
will be used as stepping stones to discover more about how astrocytes can be manipulated to
reduce disease pathology, and how circadian reprogramming could be considered in the lab when
performing experiments, and in the clinic as we decide on the appropriate times to treat patients
with drugs.
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